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Abstract
Approximately 75% of new molecular entities approved by the Food and Drug Administration
(FDA) for use in the pharmaceutical industry are found to have poor aqueous solubility. This
undesirable attribute leads to consequences such as higher doses required to reach therapeutic
levels, greater vulnerability to food effects, lesser fraction absorbed in the small intestine and
damage to the environment due to increased quantity of excretion. The addition of an excipient
(i.e. a FDA approved inactive ingredient) to the molecular structure of an active pharmaceutical
ingredient (API) through intermolecular bonding is of growing interest because the properties
of the API can be tuned without further clinical testing. Crystal engineering utilizes the
knowledge of intermolecular interactions to design new solids with improved properties (e.g.
solubility, stability, bioavailability, dissolution rates). In this thesis, these techniques are
applied to increase the solubility of three APIs with low solubility: esomeprazole magnesium,
curcumin and rufinamide. Through an extensive screening process, novel solid states were
discovered including a water/butanol solvate of esomeprazole magnesium and a co-amorphous
mixture comprised of curcumin and folic acid dihydrate. The co-amorphous mixture was found
to have increased dissolution rate compared to curcumin and can be repositioned as a prenatal
drug. Characterization of these products include powder and single crystal X-ray diffraction,
differential scanning calorimetry, thermogravimetric analysis, Fourier Transform infrared
spectroscopy, solution nuclear magnetic resonance spectroscopy and dynamic vapour sorption.
Screening of rufinamide did not lead to the discovery of any new forms, but the refined
molecular structure of the metastable form is reported.
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solid-state characterization, dissolution studies
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Chapter 1

1

Introduction

Many of the drugs that are currently or about to be introduced to the market are considered
to have low water solubility. This leads to some major issues in drug uptake that are costly
to both pharmaceutical companies and the environment. Crystal engineering is a concept
that relies on one’s knowledge of intermolecular interactions and uses this knowledge to
design new materials. A technique exploited by crystal engineering to increase the
solubility of active pharmaceutical ingredients (APIs) is to incorporate another molecule(s)
that disrupts its crystal lattice, as illustrated in Figure 1.1. Co-amorphous mixtures,
eutectics and co-crystals can all be formed when the additional molecules are neutral solids,
and a solvate occurs solvent molecules are added.

Figure 1.1: General scheme of possible solid states formation via excipient addition where
green is API; blue, yellow and orange are excipients capable of intermolecular bonding;
and blue is solvent molecules.
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Creation of these solid states requires extensive screening, which commonly uses both
computer-based and experimental techniques. Computational methods help provide a
collection of possible molecules that could be used. Used in parallel with understanding of
hydrogen and intermolecular bonding, one can come up with a comprehensive list of drugapproved excipients that would be examined. The next step is to run experiments (e.g.
solvent evaporation, grinding, melting, etc.) that will hopefully result in formation of a
novel compound. In this thesis, three poorly water soluble APIs (i.e. esomeprazole
magnesium, curcumin and rufinamide) are investigated and screened for a solid state with
increased solubility. Solvent-based and mechanical techniques are employed for the
screening of novel solid states (i.e. eutectics, co-crystals, co-amorphous mixtures and
solvates) of these APIs, and the results of these screenings are given in the succeeding
chapters.

1.1 Objectives
Esomeprazole magnesium, curcumin and rufinamide are all considered to have low
solubility in water. The main questions addressed in this thesis are:
1. How can the crystal structure of an API be engineered to form solid states that will
increase thermodynamic equilibrium solubility or kinetic dissolution rate?
2. What methods can be employed to produce these novel solid states?
3. Once formed, how will these solid states be characterized?

1.2 Motivation
The applications for low solubility APIs can be greatly increased if this undesirable
characteristic were to be improved. Since higher solubility leads to greater bioavailability
and consequently less cost due to lower dosages, the formation of novel solid states is an
attractive approach for industry. Also, due to patent laws, pharmaceutical companies are
constantly looking for unique forms of name brand drugs that are patented by other
companies so that they can also produce them. Incorporating a new molecule that disrupts
the lattice of a drug is considered innovative enough to possess its own patent, allowing
the pharmaceutical company the ability to legally produce and sell this form of the drug.
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Production of this new solid state is often done at a much lower overall cost than if the
company were to invent the drug from the beginning stages. For instance, if a novel solid
state is formed with an excipient or solvent that is already approved by the FDA, then allinclusive clinical testing (i.e. that for a novel drug) does not need to be conducted since the
therapeutic effects of the API are already known. Not only does this save money, but it will
also save the company a lot of time. These techniques are especially helpful for companies
that create generic drugs that tend to be sold at a much lower cost.

1.3 Background
1.3.1

Esomeprazole Magnesium

In 2004-2005 alone, $52,235,910 was spent by the Canadian health care system on patients
with a primary diagnosis of esophagus related diseases, including gastroesophageal reflux
disease (GERD).1 GERD often causes chronic heartburn, which can lead to degradation of
the lining in the esophagus. Many of the symptoms related to GERD (i.e. those listed in
Table 1.1) can be avoided if the disease is treated early enough by the use of a proton pump
inhibitor (PPI).2 A very common and effective PPI is omeprazole.
Table 1.1: Some symptoms and complications of GERD.2
Common

Uncommon

Complications

Heartburn

Hoarseness and sore throat

Erosive esophagitis

Regurgitation

Difficulties swallowing

Esophageal stricture

Sleep Disturbance

Asthma and sinusitis

Ulceration and bleeding

Early Satiety

Vomiting

Esophageal cancer

Upper abdominal

Nausea

Upper respiratory

distension

complaints
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Esomeprazole (Figure 1.2 (b)), the (S)-isomer of omeprazole, was the first isolated single
isomer PPI.3 It is currently marketed by AstraZeneca as the trihydrate form of the
magnesium salt under the name Nexium (Figure 1.2 (a)). When compared to other PPIs
(i.e. lansoprazole, pantoprazole, omeprazole and rabeprazole), esomeprazole was found to
provide more effective control of gastric acid at the standard dose of 40 mg/day. 4 However,
it is considered only slightly soluble in water.

(a)

Nexium

(b)

Figure 1.2: (a) Nexium, the marketed version of esomeprazole magnesium and (b)
the structure of esomeprazole.

The synthesis of esomeprazole on a large scale involves asymmetric oxidation of the same
intermediate in the synthesis of omeprazole. Once coordinated to the Mg center,
esomeprazole magnesium is found to contain only the (S)-isomer. The scheme, starting
from the intermediate, is given in Figure 1.3.5

Figure 1.3: Synthesis for large scale production of esomeprazole magnesium that
results in sole presence of (S)-isomer of omeprazole.
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1.3.2

Curcumin

Turmeric, or curcuma longa, is a root belonging to the ginger family and is very common
in Asian cuisine (Figure 1.4 (a)). The principal curcuminiod found in turmeric is curcumin;
though, desmethoxycurcumin, bis-desmethoxycurcumin and cyclic curcumin are also
present. Curcuminoids are very yellow in appearance due to the polyphenols and can be
orange if there is conjugation in the chain, which is illustrated by curcumin in Figure 1.4
(b).6 Curcumin is a tautomer and is also present in a diketo form, but the ketol-enol
tautomer shown below is found to be more stable and is also more effective as a drug. 7

(a)

(b)

Figure 1.4: (a) Curcuma longa, also known as turmeric root, is a common
spice used in Asian cooking and (b) the chemical structure of curcumin, the
principle curcuminoid found in turmeric, in the stable ketol-enol form.
Curcuminoids make up only 2-9% of the turmeric root, so the extraction process is critical.
Curcumin can be extracted from turmeric via many different processes, such as solvent
extraction, Soxhlet extraction, microwave extraction, ultrasonic extraction, use of
supercritical CO2, etc. followed by column chromatography. The most frequently
employed method is the use of solvent extraction with ethanol (EtOH) due to its capacity
to be used in food and pharmaceutical processes as well as curcumin’s high solubility in
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EtOH. In regions where turmeric is not grown in abundance, a more viable method is to
synthesize it. A simple synthesis route is given in Figure 1.5 that has been adopted by
many.8 This method generally involves reacting 2,4-diketos with substituted aromatic
aldehydes. Boron trioxide is employed to form a complex that prevents the keto groups
from partaking in condensation reactions. The primary amine is used as a catalyst, while
alkyl borate is a water scavenger to increase curcumin yields. Hydrochloric acid (HCl) is
the last step to dissociate the boron complex.9

Figure 1.5: General synthesis route of curcumin that is widely used.
Curcumin extract has been shown to have many different uses and valuable health effects.
Some of these include antioxidant10 and anti-inflammatory effects11, use as a colorimetric
sensor12, tumor reducer13, prevention of type 2 diabetes14, etc. Many Asian countries,
especially India, see the benefits of using turmeric since it is usually cooked in oil, which
acts as a solvent to dissolve curcumin and allows for better uptake. Turmeric is not as
common in Western countries, and some are not accustomed to the taste. This often leads
to curcumin being taken in pill form, which greatly decreases the bioavailability. 15 If the
solubility of this drug could be increased, then its use in various distinct applications would
be much more feasible.

7

1.3.3

Rufinamide

Lennox-Gastaut is a catastrophic form of child epilepsy that has its onset from 1-7 years of
age and tends to continue into adulthood. This syndrome and the impact of its seizures
requires a group of health professionals to support the child and the family.16 Though first
discovered in the 1930s, Lennox-Gastaut syndrome was later defined as a very severe form
of childhood epilepsy characterized by frequent and multiple types of seizures, mental
retardation and slow spike-wave electroencephalographic (EEG) patterns.17 Common
drugs that are used to treat these seizures include clobazam, lamotrigine, rufinamide,
topiramate and valproate.
Rufinamide, marketed as Banzel by Eisai Co., is a triazole derivative with low aqueous
solubility. It is produced as both a tablet and oral solution (Figure 1.6 (a)). The chemical
structure is shown in Figure 1.6 (b); there is a lot of potential for intermolecular interactions
with rufinamide due to the amide group, aromatic fluorine and lone pair electrons of the
triazole ring. This leads to the investigation of possible novel solid states (such as those in
Figure 1.1) that is described in Chapter 5.

(a)

(b)

Figure 1.6: (a) Banzel in tablet form (200 or 400 mg) or oral solution, and (b) chemical
structure of Rufinamide. 21
Rufinamide is generally synthesized through one of the three routes depicted in Figure 1.7.
To construct the triazole core, all three routes employ 1,3-dipolar Huisgen cycloaddition
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of 2,6-difluorobenzylazide with a dipolarophile. Route (c) is commonly used as it uses low
cost starting materials, does not require catalyst and can be produced continuously.
Rufinamide can also be synthesized using continuous flow copper tubing reactor-catalyzed
cycloaddition reaction.18

Figure 1.7: Synthesis routes for rufinamide where schemes (a), (b) and (c) employ (E)methyl 3-methoxyacrylate, propiolic acids/esters and 2- chloroacrylonitrile,
respectively. Routes (b) and (c) rely on amidation in the final step, while route (a) uses
hydrolysis.18–20
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1.4 Thesis Outline
Chapter one provides a brief introduction to the low solubility APIs addressed in this thesis.
The objectives and motivations of the work in this thesis are also given.
A literature review of solid state formation by excipient addition is presented in chapter
two. The subject matter included is the formation and characterization of co-amorphous
mixtures, co-crystals, eutectics and solvates.
In chapter three, a novel esomeprazole magnesium solvate with water and 1-butanol is
described. The molecular structure shows how esomeprazole co-ordinates to magnesium
for the first time. Full characterization is given.
Chapter four presents the research conducted on curcumin, including the formation of a
novel co-amorphous mixture with folic acid dihydrate that displays increased dissolution
rate and has potential as a prenatal drug. Work on solid state screening and formation of
form II is also available.
Chapter five highlights the screening conducted with rufinamide. While no novel solid
states were presented in this chapter, the molecular structure of modification B is illustrated
along with a unique method to produce this metastable form.
The final portion, chapter six, gives a conclusion on the entire thesis and provides
recommendations for future works.
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Chapter 2

2

A Review of Crystal Engineering via Non-Ionic Excipient
Addition to Increase Drug Solubility and Bioavailability

Approximately 75% of the drugs that are being approved for use in the pharmaceutical
industry have low aqueous solubility. This leads to issues with drug uptake, higher doses
and consequently a negative environmental impact. One approach to improving these
active pharmaceutical ingredients (APIs) is to use the crystal engineering technique of
adding another molecule that disrupts the crystal lattice of the API. This method relies on
the knowledge of the intermolecular bonds that the API can form with the excipient and
employs many different synthesis techniques. The formation of a novel solid state is
dependent on the strength of the intermolecular bonds formed and the type of synthesis
used. Main synthesis routes include a variety of solution crystallization procedures as well
as liquid assisted or neat grinding. This review will emphasize the formation of new states
by incorporating a distinct molecule through non-ionic bonding with the API. For this
reason, polymorphs and salts will be disregarded and the main forms analyzed are coamorphous materials, co-crystals, eutectics and solvates. Once formed, the proper
characterization procedure and the methods of distinguishing these solid forms are
discussed. Appropriate choice of excipient as well as screening methods are also given in
detail.

2.1 Introduction
Every year the Food and Drug Administration (FDA) approves new molecular entities
(NMEs) for pharmaceutical use; as of May 2017, there have already been 20 active
pharmaceutical ingredients (APIs) accepted, this year. A biopharmaceutics classification
system (BCS), depicted in Figure 2.1 is used by the FDA to classify APIs and reduce
unnecessary human testing.1 The BSC goes as follows: Class I (high permeability, high
solubility); Class II (high permeability, low solubility); Class III (low permeability, high
solubility); and Class IV (low permeability, low solubility). 2 When combined with
dissolution studies, a biowaiver for in vivo bioavailability and bioequivalence can be
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applied for Class I and III drugs, which leads to a less vigorous testing required for these
drugs.3

Figure 2.1: BCS used by the FDA where highly soluble is considered when the
highest dose strength is soluble in less than 250 mL water over a pH range of 1 to
7.5, and highly permeable is considered when the extent of absorption in humans
is determined to be greater than 90% of an administered dose.1
A simple solution to help pharmaceutical companies with more efficient drug testing (i.e.
less clinical testing) would be to stop using drugs that do not belong to Class I and III;
however, approximately 75% of NMEs belong to BCS Class II and IV. 4 This means that
majority of effective medicines that are FDA approved drug innovations have a poor
solubility in aqueous solutions. Many drugs today are designed using high throughput
screening approaches to ensure valuable and successful products. Since the approval
process for NMEs takes years, pharmaceutical companies want to guarantee that they have
the best contenders. The screening processes tend to result in APIs that are higher in
molecular weight and have increased hydrogen-bonding.5 Increased molecular size results
in greater van der Waals interaction between like molecules, while more hydrogen bonding
within the API creates a stronger crystal lattice. Both characteristics lead to a compound
that is more difficult to dissolve.
Why are low solubility drugs undesirable? First, they often require high doses to reach
required therapeutic plasma concentrations after oral administration, hence patients are
ingesting significantly more than necessary. The increase in dose also leads to more costly
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medicines, which is unfavourable to consumers and pharmaceutical companies. Poorly
soluble APIs are also more vulnerable to food effects (e.g. some drugs are suggested to be
taken after a fasting period due to reduced absorption in the presence of food), and slow
dissolution can lead to lesser fraction absorbed in the small intestine. 6 High levels of API
excretion due to low absorption are costly to the pharmaceutical industry and can be
detrimental to our environment. For instance, carbamezapine, a routine API that is nearly
insoluble in water, was found in every sample taken from wastewater treatment plants’
effluent of three different rivers in England.7 Therefore, not only are Class II and IV drugs
more expensive to administer, they also have a lasting effect on the Earth. Taking these
factors into account, a strong need to increase the solubility of these drugs is prevalent.
Crystal engineering is defined as: the understanding of intermolecular interactions in the
context of crystal packing and the utilization of such understanding in the design of new
solid forms with desired physical and chemical properties.8 Numerous methods are present
that involve altering the solid state of Class II and IV APIs to increase water solubility and
bioavailability. This altering of states is known as crystal engineering, and some of these
approaches include formation of: salt, co-crystal, solvate, eutectic and co-amorphous
mixture. The bioavailability of a drug is affected by its aqueous solubility, dissolution rate,
permeability, etc. If one can increase the water solubility of Class II drugs, the
bioavailability will be greatly improved.9
In this chapter, the practices discussed will focus on non-ionic bonding between distinct
molecules, so salts and polymorphs will be overlooked. The techniques mentioned involve
adding another component called an excipient into the crystal structure; excipients will
usually have more ideal physical and chemical characteristics than the API, so the
combination will lead to a superior drug product. The beauty of these methods relies on the
fact that excipients are already approved by the FDA for use in pharmaceuticals, and thus,
the novel solid state of the API will not need to undergo new clinical studies.
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2.2 Co-amorphous Mixtures
An amorphous solid, also referred to as a glass, has no long range molecular order of
packing nor does it have a distinct molecular conformation.10 Amorphous materials have
properties similar to liquids at a molecular level but are more like solids at a macroscopic
level.11 Due to the lack of order and since this form is the most energetic, amorphous
compounds have been shown to have increased solubility in comparison to their crystalline
counterparts.12 Consequently, this will also result in an increase in bioavailability, so the
formation of an amorphous pharmaceutical compound is an appropriate means to tackle
the issues with Class II and IV drugs.
Co-amorphous solids, depicted in Figure 2.2 (c), occur when two components become
amorphous due to interaction with one another. Intermolecular bonding between API and
excipient impedes the arrangement of individual molecules into separate lattices and results
in an amorphous material.13 Co-amorphous mixtures are shown to be not only high in
solubility, but have a high stability.14 By adding another component into the system, the
problem of low stability in amorphous materials is alleviated in co-amorphous materials.
Amino acids are great candidates as excipients in these systems.15

(a)

(b)

(c)

Figure 2.2: Representation of (a) crystalline API (green) and
excipient (yellow), (b) amorphous API, and (c) co-amorphous
API and excipient.
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An amorphous phase composed of a single material can be created through two main routes
of production: either a thermodynamic or kinetic disordering processes. Thermodynamic
disordering occurs when the loss of long range order symmetry causes disorder in the solid
state. It allows for close random packing and is termed thermodynamic disorder due to the
breaking of symmetry.16 Kinetic disordering is referred to when long range disorder is
caused by short range order. This process is considered to be continuous and can reduce
crystalline material to glassy material.17 When creating an amorphous state, the
thermodynamic pathway involves starting with a thermodynamically stable non-crystalline
form, such as a melt or solution. The melt will then undergo quenching, while the drug will
be precipitated from solution. Conversely, the kinetic pathway will start with a solid state
which is then converted by introducing crystal defects via crushing, milling and continuous
shear forces.18 These pathways are also applicable to the synthesis of co-amorphous
systems.
While still quite a new practice in drug formulations, co-amorphous mixtures have been
shown to be readily obtained by a variety of procedures. The main procedures are milling
and grinding (kinetic disordering) or quenching and solvent evaporation (thermodynamic
disordering). Given in Table 2.1 are some instances of co-amorphous mixtures and the
methods used to produce them. These are all desirable techniques because not only are they
quick to produce, they also only require a small amount of sample; however, not every
technique is applicable to every drug-excipient combination. Quenching is not available if
degradation occurs at higher temperature, solvent evaporation can prove difficult if there
are solubility differences, and milling may not apply enough force to disrupt the lattice.
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Table 2.1: Preparation of Co-amorphous Systems.
Drug

Excipient Technique

Experimental

(or drug)
Curcumin

Artemisinin

Solvent

A mixture of 1:1 molar ratio of curcumin and

Evaporation

artemisinin was dissolved in ethanol. The solution was
then rotovaped (fast evaporation under vacuum) to
give the co-amorphous product.19

β-azelnidipine

Maleic

Grinding

β-azelnidipine and maleic acid at molar ratios of 1:1

Acid

(LAG or neat)

and 1:2 were placed into a 50 mL stainless steel jar and
milled at 30 Hz in a laboratory-scale oscillatory disk
mill. This can be done neat or with the addition of
ethanol.20

Indomethacin

Cimetidine

Quenching

Indomethacin–cimetidine physical mixtures were
melted on an aluminium foil placed on a preheated
hotplate (180°C) for 1 min. The molten liquid was
cooled quickly by placing the aluminum foil over ice
water.21

To classify a material as amorphous, perhaps the most effective method is to use powder
X-ray diffraction (PXRD). Crystalline material will show very distinct and sharp peaks,
while amorphous material will appear as one very broad peak termed a halo since it has no
defined crystal lattice or symmetry operators. To further examine the characterization of a
co-amorphous system, the first example in Table 2.1 will be considered. Curcumin, a
poorly water soluble molecule, has been shown to help increase anti-malaria effects when
taken in parallel with the API, artemisinin. Instead of prescribing these and taking them
separately, a co-amorphous mixture was formed via fast solvent evaporation so that a
patient could take them together. The PXRD patterns of the starting materials and the
mixture are shown in Figure 2.3.19 It is clear that the mixture has lost the crystalline nature
of the starting materials and is now forming weak intermolecular interactions.
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Figure 2.3: The PXRD patterns of crystalline curcumin
form I (blue), co-amorphous curcumin-artemisinin
(purple), and crystalline artemisinin form I (pink).19

Depending on the method used for producing the co-amorphous mixture, obtaining an
amorphous pattern from PXRD is sufficient for characterization. If prepared via grinding,
then the product is usually co-amorphous; however, quenching may lead to degradation
and solvent evaporation could lead to a single amorphous state precipitating out first. To
ensure that both starting materials are present in the amorphous product, one should
perform solution 1H NMR (nuclear magnetic resonance). If the shifts seen are solely
representative of both starting materials, then the product can be said to be co-amorphous.
Keeping with the curcumin-artemisinin mixture, it was exhibited that chemical shifts for
both starting materials were present in their product.
Solid state NMR (ssNMR) is another method that can be used for the characterization of
these systems. ssNMR will usually show broader bands for amorphous material compared
to crystalline material due to the increase of molecular orientations. 22 There will also be a
shift in peaks due to the intermolecular bonding between the drug and excipient.23
Furthermore, when compared to the ssNMR spectrum of a purely crystalline homogeneous
mixture of the starting materials, the amorphous content of the co-amorphous system can
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be determined.24 However, this technique often relies on peak integration, which can prove
to be difficult when there is an overlap (i.e. broad peaks in amorphous materials often result
in overlap). Also, formation of the homogeneous mixture could result in decreased
crystallinity that would introduce error. Another method is to compare with both the fully
crystalline and fully amorphous spectra of the starting materials. This method uses
principal components analysis (PCA) of ssNMR data that is normalized by dividing all
PCA scores by the score of the 100% amorphous sample after subtracting the score of the
crystalline sample. The profile for rate of co-amorphization can be obtained by plotting the
normalized data against mill time.25
For further characterization, Raman and FT-IR (Fourier Transform Infrared Spectroscopy)
can be conducted. For both techniques, the spectra will appear as a combination of the
starting materials with small shifts in frequencies.26 The peaks that have shifted when
compared to the starting materials, are representative of the bonds involved in the
intermolecular bonding that stabilizes and causes formation of co-amorphous mixtures.27,28
When coupled with ssNMR, these characterization techniques are useful in proposing a
bonding mechanism between components of the system. Following the ongoing example,
the proposed bonding mechanism of curcumin and artemisinin in Figure 2.4 was
determined by analyzing the FT-IR spectrum, which showed a shift in carbonyl stretching
of artemisinin and the phenolic alcohol of curcumin.

Figure 2.4: Proposed bonding mechanism in the co-amorphous
system of curcumin-artemisinin.19
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Fundamental thermal analysis of these systems is done by differential scanning calorimetry
(DSC). Amorphous materials will undergo a glass transition at a specified temperature (Tg),
above which the material will tend to crystallize.29 The DSC data of a co-amorphous system
will vastly differ from that of the starting materials. Once again considering the Curcuminartemisinin system, the differences can be appreciated in Figure 2.5. The melting of the
starting materials is seen in the endothermic peaks, while the co-amorphous system has a
broad exotherm. The Tg is highlighted and appears below the melting of both curcumin and
artemisinin. When plotting a phase diagram of a binary system using DSC, a “v” shape
may appear for co-amorphous mixtures with a single thermal event happening at a
particular molar ratio.30 Since co-amorphous systems are not well studied, using DSC alone
is not useful as its results are not universal (e.g. the formation of a “v” in the binary phase
diagram is an ideal situation).

Figure 2.5: DSC thermographs of curcumin (black), amorphous
curcumin (red), co-amorphous curcumin-artemisinin system (blue) and
artemisinin (green). Circled are the glass transition temperatures.

Since amorphous materials are not crystalline, single crystal XRD cannot be obtained.

2.3 Co-Crystals
Much like co-amorphous systems, a co-crystal is composed of neutral, solid components
that interact with each other through intermolecular bonding. A simple depiction of a 1:1
molar ratio co-crystal comprised of two different compounds is given in Figure 2.6. In this
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representation, the green component can be the API, while the orange is the excipient.
Intriguingly, one of the components can be comprised of a salt or hydrate so long as each
component is considered overall neutral.31,32 Co-crystals have been known for some time
by different names (e.g. addition compounds, mixed binary molecular crystals, molecular
complexes, solid-state complexes, heteromolecular crystals, etc.), but have not been of
great interest until recently.
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To avoid being ambiguous between solid states, the FDA

gave the following definition to co-crystals: solids that are crystalline materials composed
of two or more molecules in the same crystal lattice.34 In a pharmaceutical co-crystal, at
least one of these components will be an API; the excipient is referred to as the co-crystal
former or co-former.35

Figure 2.6: Representation of a two-component
co-crystal in a 1:1 molar ratio, where both green
and orange represent a solid, neutral component.
Co-crystallization occurs when an excipient is introduced that competes with and
supersedes the intermolecular bonding of a molecule with itself. 36 The most difficult task
in co-crystal formation is picking an appropriate co-former, which will be discussed later
on. The main intermolecular force behind co-crystal formation is hydrogen bonding, so the
co-former should have appropriate hydrogen bond donors (HBD) and acceptors (HBA).
There are additional contributing factors to co-crystal formation, and a statistical review of
co-crystals in the CSD (Crystal Structure Database) leads to some general assumptions:
co-crystals form between molecules of similar shape and polarity, and the number of
HBD/HBA is less important than the strength of the potential hydrogen bonding. 37 For
instance, if an API has multiple functional groups and one is carboxylic, it will tend to have
greater potential forming a co-crystal with an excipient containing an amide than with an
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excipient that can form multiple weaker bonds. Furthermore, if an API shows potential for
intermolecular bonding with an excipient due to matching the HBD and HBA groups, a cocrystal may not form if the shapes do no match (e.g. planar molecules will tend to form cocrystals with planar molecules).
The formation pathways for co-crystallization are comparable to those for co-amorphous
mixtures and include liquid assisted (LAG) or dry/neat grinding, solvent evaporation,
isothermal slurry conversion, cooling crystallization, anti-solvent crystallization, spray
drying and rapid expansion of supercritical fluids. Provided in Table 2.2 is a summary
which highlights examples of each method.
Table 2.2: Some Preparation Techniques for Co-Crystal Synthesis.
Drug

Co-former

Technique

Experimental

Theophylline

Citric Acid

Neat

0.150 g of an equimolar combination of theophylline and

Grinding

citric acid was placed into a 25 mL stainless steel
grinding jar and ground for 1 h using two stainless steel
balls 7 mm in diameter. The overall temperature of the
reaction mixture remained below 35 °C.38

Adefovir

Glutaric Acid

LAG

Dipivoxil

1:1 mole ratio of adefovir dipivoxil and glutaric acid was
ground using an agate mortar and pestle for 20–30 min.
Methanol was added dropwise over the course of
grinding (0.5 mL/mmol cocrystal).39

Fenofibrate

Nicotinamide

Solvent

A mixture of FNO and nicotinamide in 1:1 molar ratio

Evaporation

was dissolved in 20 mL of ethanol with sonication (to
induce saturation) and was kept overnight to evaporate
solvent. The crystals obtained after evaporation of
ethanol were dried in air.40

Trospium

Salicylic

Chloride

Acid

Quenching

A 1:1 physical mixture of trospium chloride with
salicylic acid was prepared and heated at 10°C per min
under nitrogen purge above eutectic temperature. The
mixture was then cooled to room temperature at a
cooling rate of 10°C per min. After the mixture stood at
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30°C for 60 min, the heating was repeated and the cocrystal was obtained.41
Indomethacin

Saccharin

Anti-solvent

In a 1L double jacketed reactor, predetermined amounts

Addition

of indomethacin and saccharin were fully dissolved in
methanol (300 mL), and 150 mL of purified water as
anti-solvent was added to the solution using a peristaltic
pump. The process was performed for 30 min and the
product was filtered and dried under vacuum.42

Theophylline

Glutaric Acid

Slurry

Equimolar mixture of theophylline and glutaric acid

Conversion

was added into chloroform to form slurry at 50°C. This
slurry was seeded with crystals from co-grinding of
theophylline and glutaric acid and co-crystals formed as
solvent evaporated.43

Theophylline

Saccharin

Spray

A 0.9% equimolar solution of theophylline and

Drying

saccharin in ethanol were spray dried at an inlet
temperature of 120°C and outlet temperature of 77°C to
give a co-crystal. The feed rate was 5 mL/min, the air
flow was 536 L/h and the aspiration was 100%.44

The most advantageous way to characterize a co-crystal is by growing single crystals and
running X-ray diffraction. This technique will give the stoichiometric ratio, crystal lattice
and intermolecular bonding of the molecular structure.45–48 Single crystal X-ray diffraction
method alone is adequate in declaring that there is positive formation of a co-crystal.
However, while it is the most useful, obtaining single crystals is an art, and it is not always
possible. Since many co-crystals are formed using mechanochemical techniques, single
crystals are often not achievable.49 Also, changing to conditions necessary to form high
quality crystals can sometimes cause components to crystallize independently. In these
scenarios, other techniques can be employed to characterize the suspected co-crystal.
ssNMR is a practical characterization technique in helping elucidate the structure of the
co-crystal formed. It has even been shown that ssNMR can be used to monitor co-crystal
formation in situ.50 This method can be used for small amounts of sample, is non-invasive
and can adequately analyze multiphase systems. 51 Using 1D and 2D ssNMR techniques
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can lead to the determination of the intermolecular bonding sites within the co-crystal.52
When coupled with PXRD and density functional theory (DTF) calculations, 1D ssNMR
can be employed to determine the molecular structure of a co-crystal. For example, a
theophylline-nicotinamide co-crystal has been formed by LAG or slow evaporation with
ethanol and is shown to have improved solubility and hygroscopicity than anhydrous API. 53
Characterization techniques and crystal engineering knowledge were used to interpret
intermolecular bonding sites in the co-crystal. Next, this suggested bonding between API
and excipient was refined using DTF method, and the

13C

and

15N

ssNMR spectra were

predicted. These were then compared to the spectra that were obtained experimentally and
validated the refined structure of the theophylline-nicotinamide co-crystal.54
PXRD is also particularly useful; if a co-crystal is formed then the crystal lattice will
change, resulting in a powder pattern that is distinct from the starting materials. This
concept can be easily visualized by examining the theoretical PXRD patterns of an API,
co-former and their corresponding co-crystal in Figure 2.7. It has also been demonstrated
that PXRD can be utilized to help determine the purity of the co-crystal formed. This is
done by formation of a calibration curve using known amounts of co-crystal and then
monitoring the most intense peak in the PXRD pattern that has the least amount of
overlapping.55

(a)

(b)

(c)
2
Figure 2.7: Theoretical PXRD patterns of (a) API
(b) co-former and (c) their co-crystal.
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Thermal analysis is also critical in the analysis of co-crystals.56 Akin to the PXRD patterns,
DSC thermographs will result in data that is different from the starting materials. The
thermographs of co-crystals usually show an endothermic peak for co-crystal melting that
is above or below the melting of the API and co-former.57 Ideally, the co-crystal will have
a lower melting point than the API; this will result in bonds that are easier to break and
increase the drug’s aqueous solubility.58 DSC can also be employed to prepare a phase
diagram for the system. When plotting the onset of peak one and the peak temperature of
peak two at varying molar ratios, the result is a sort of “w” shape. 59 The region between
the two eutectic peaks is the co-crystal forming region. This phenomenon is more suitably
explained with the aid of an image (Figure 2.8).60
Onset of the

Co-crystal forming region

Temperature

eutectic melt

Co-crystal melting

0

100
% Co-former

Figure 2.8: Theoretical phase diagram of a
binary system capable of co-crystal formation.
Obtaining PXRD and DSC data that validates the presence of a co-crystal is sufficient in
claiming co-crystal formation. To acquire the stoichiometric ratio, integration techniques
of solution 1H NMR can be employed.61 For example, if a single proton in the API is
normalized to one and a chemical shift representing three protons in the excipient integrates
to three, then the co-crystal ratio is 1:1 API:co-former. If single crystal XRD and/or ssNMR
have been attained, then Raman and FT-IR are not necessary. However, if not attained,
these techniques will show a change in stretching frequencies which will imply that certain
bonds are involved in intermolecular bonding and help to determine what supramolecular
synthons (see Section 2.5) are being formed.62,63 DSC can be coupled with FT-IR as a very
quick and easy means of co-crystal confirmation. By comparing the changes in IR
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frequencies as a binary system is heated, one can confidently see where co-crystal
formation occurs.64 Often times a combination of all or multiple techniques that have been
mentioned are used to ensure a complete characterization so that co-crystal formation is
irrefutable.

2.4 Eutectics
Like co-crystals and co-amorphous mixtures, eutectics are comprised of multiple
components that are neutral at ambient conditions. A pharmaceutical eutectic mixture is
comprised of API(s) and excipient(s) that do not interact to form a novel compound, but
will impede the crystallization of each other at certain molar ratios. 65 These interactions
are short ordered and are not seen over a long range. 66 Formation of eutectic mixtures is a
useful method for weakening the intermolecular bonding of a crystalline material. This will
reduce the melting point of a system, which will ultimately increase the solubility. The
solubility is also increased due to the reduction in particle size (and consequently the
increase in surface area) found in eutectics compared to the separate crystalline
components.67 Figure 2.9 is a visualization to help comprehend the concept of eutectics: if
the green and purple characters shown in (a) are representative of the crystal structures of
API and excipient, then (b) and (c) are ways in which they can interact. These different
types of interactions will be found discontinuously within the eutectic mixture and can
interact with each other.68 The components of a eutectic mixture are miscible in the liquid
state, but only slightly in solid state. At a eutectic composition, the API and excipient will
crystallize out at the same time, while at any other molecular ratio one component will start
to crystallize distinctly.69
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(a)

(b)

(c)

Figure 2.9: (a) molecular structures of API (green) and excipient (purple), (b) and (c) are
both examples of discontinuous interaction between API and excipient found in eutectic
mixtures. These interactions can interact with each other throughout the mixture. 68
The synthesis of eutectic mixtures is comparable to that of other solid states. Usually the
same techniques are employed and will simply result in a eutectic instead of a co-crystal
or co-amorphous mixture due to the strength of the interactions between API and excipient.
The most common techniques include melting, grinding and solvent evaporation; some
examples are displayed in Table 2.3.
Table 2.3: Cases Representing Some Synthesis Techniques of Eutectic Mixtures.
Drug

Excipient

Technique

Experimental

Grinding

Curcumin and nicotinamide were taken in a

(or drug)
Curcumin

Nicotinamide

stoichiometric ratio and subjected to solid-state
grinding in a mortar-pestle for 15 min.70
Acetaminophen

Caffeine

Melting

A stoichiometric mixture of acetaminophen and
caffeine was heated to a temperature 2°C above
complete fusion of both compounds. The mixture was
stirred, cooled to room temperature and gently ground
(using a mortar and pestle).71

Aspirin

Paracetamol

Solvent

A different proportion of aspirin and paracetamol was

Evaporation

dissolved in a methanol:dichloromethane (3:1) solution;
the solvent was evaporated rapidly under vacuum.72
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Eutectic mixtures are an emblematic product when screening for pharmaceutical cocrystals; consequently, the same techniques are employed for characterization. The initial
step is typically to run PXRD due to its capacity for rapid analysis. The PXRD pattern for
a eutectic mixture differs from that of co-crystals and co-amorphous mixtures since they
are characterized by a pattern that is a combination of the starting materials (similar to a
physical mixture) as opposed to one that is unique.73 This distinguishing characteristic is
due to API and excipient retaining their molecular structures while still comprising of
intermolecular bonding.
Obtaining a PXRD pattern of this nature is not sufficient for eutectic confirmation as it may
simply be a physical mixture of the components; the next step in characterization would be
DSC. The thermograph for a eutectic mixture will usually appear as a melting endotherm
that occurs at a temperature below both API and excipient melting. 74 A physical mixture
differs and will show two distinct melting points, since the constituents are not
interacting.75 At a specific ratio, this endotherm will appear as a single peak resembling a
co-crystal; however, since the PXRD pattern is not distinct, it is known to be a eutectic and
no exothermic events will occur.59 Running DSC at different molar ratios and plotting the
binary phase diagram (as previously described) will result in a graph that has a “v” shape
similar to Figure 2.10.
Eutectic melting point

Temperature

Liquid region

0

100

% Excipient

Figure 2.10: Theoretical phase diagram of a
binary system which forms a eutectic.
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These two techniques, PXRD and DSC, are typically sufficient in determining if a eutectic
has formed. Solution 1H NMR can be run to confirm stoichiometric ratios. FT-IR, Raman
and ssNMR will all mirror PXRD in terms of obtaining result that reflect a combination of
the starting materials.70 Confocal Raman Microscopy has been employed to show
discontinuous bonding in eutectic mixtures by monitoring characteristic bonding peaks. 76

2.5 Solvates
Contrary to the previous solid states that have been discussed and consist exclusively of
solid materials at room temperature, a solvate is comprised of multiple components where
solvent(s) has been incorporated into the crystal lattice.77 A special case, termed a hydrate,
occurs when solvent involved is water.78 Liquid solvent at ambient conditions can be found
in both stoichiometric and non-stoichiometric amounts, as depicted in Figure 2.11.79 A
solvate is described simply as any crystal composed of a solvent molecule and either a coformer or a cation-anion pair (Figure 2.11(c)). When the components are found in
stoichiometric amounts, this is referred to as a “true solvate” (Figure 2.11(b)).80

(a)

(b)

(c)

Figure 2.11: Representation of (a) crystalline API (green) and solvent
(blue), (b) stoichiometric or ‘true” solvate, and (c) non-stoichiometric
solvate.
Pharmaceutical solvates will contain an API as a co-former or pharmaceutical salt as the
cation-anion pair. Solvent can incorporate into the voids of the crystal lattice and is
recognized as channel solvent.81 These types of solvates will retain their crystal structure
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if the solvent is removed and can be found in stoichiometric or non-stoichiometric
amounts.82 Another type involves stronger intermolecular bonding between the solvent and
the solid that results in a distinct and more stable crystal lattice. In this scenario,
functionality is a more vital factor in solvent inclusion. 83 The extent of stabilizing,
intermolecular bonding found in these solvates includes: hydrogen bonding, halogen
binding, metallic bonding and Van der Waals Interactions.84,85
Since solvent (especially water) is present in many stages of pharmaceutical production,
solvates are an interesting means of increasing the solubility and stability of drugs. Water
and many other solvents have potential to form strong hydrogen bonding interactions with
a variety of molecules that could result in the formation of a crystal lattice with increased
stability. Removing solvent can lead to the decomposition of the API or ruin its crystal
lattice.86 Instead of trying to remove solvent from the system as waste, alternatively, it can
be incorporated (so long as it is safe for ingestion).
Synthesis of solvates is usually achieved via cooling and/or evaporative crystallization
from solution. Both methods rely on supersaturation to promote crystal growth. Solvates
have also been formed via grinding.87 A case for the synthesis of each type of solvate is
given in Table 2.4.
Table 2.4: Cases Representing the Synthesis of Different Types of Solvate Systems.
Drug

Solvent

Solvate Type

Experimental

Atorvastatin

Isopropanol

Stoichiometric

Atorvastatin

Channel

isopropanol just below boiling point for over 24

was

stirred

in

acetone

and

hours. The solution was filtered, water added as
anti-solvent and the product is allowed to
crystallize in air at room temperature.88
Sitagliptin L-

Water

tartrate
Dirithromycin

Cyclohexane

Non-stoichiometric

Solvate was crystallized from a 2-propanol:water

Channel

(8:2, v/v) mixture in air at room temperature.89

Stoichiometric

Solvate isolated by vapor diffusion of cyclohexane

Lattice Inclusion

into a toluene solution of Dirithromycin.90
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After a solvate has been formed, one needs to properly characterize it. Once again, single
crystal XRD is the all-telling technique for characterization. The data obtained will result
in the molecular structure which can be used to establish the intermolecular bonding
between components, whether a “true solvate” has been formed, if the solvent is located
predominantly in the voids, and much more. To explore this method, an Esomeprazole
Magnesium solvate, displayed in Figure 2.12 and discussed in detail in Chapter 3, will be
investigated. Esomeprazole Magnesium is a poorly soluble pharmaceutical salt with low
stability. In this solvate, water is bonded in two distinct modes: strong dative-covalent
bonding directly with Mg and in the voids of the crystal lattice. The former water molecules
are bonded more powerfully than the latter. The 1-butanol molecules are also found in the
channels and can be seen to form hydrogen bonds with water. This compound is determined
to be a “true solvate” with respect to the water molecules, and butanol is found in nonstoichiometric amounts.

Figure 2.12: Esomeprazole Magnesium solvate with
water and 1-butanol. Hydrogen bonding between
molecules is shown in blue.79
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Since single crystals are not easily attainable, there are a variety of other techniques that
can be used for characterization. PXRD is particularly useful when the solvate is
synthesized via the formation of a new crystal lattice that incorporates the solvent. This
will result in a PXRD pattern that is novel in comparison to the API. 91 Conversely, if the
solvent is simply filling the voids in the crystal lattice, the PXRD pattern will appear to be
analogous to that of the API with very slight differences. In this situation, it is necessary to
conduct further analysis, such as ssNMR, to ensure that a solvate has indeed been formed. 92
An outstanding illustration of this is seen in Figure 2.13; 13C ssNMR spectra is taken for a
non-stoichiometric solvate where solvent is found in the channels. The solvate is then
heated to remove solvent and the resulting spectra are observed, while PXRD patterns
showed no differences as the solvent was removed.93

Figure 2.13: 13C ssNMR of a non-stoichiometric, channel
solvate LY297802 tartrate at (a) ambient conditions, (b)
elevated temperature with solvent removal, and (c)
elevated temperature with increased solvent removal.93
Dynamic Vapor Sorption (DVS) is another valuable tool in analyzing pharmaceutical
solvates. This instrument measures the mass of a sample with respect to changes in relative
humidity (RH). For example, if a hydrate-forming API is put into an environment of
increasing humidity, a change in mass is seen during hydrate formation. The additional
mass will correspond to the ratio of water incorporated into the system, and the graph will
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form a hysteresis, such as the one shown in Figure 2.14.94 This technique can also be used
with other organic vapors to determine solvate formation. 95 Solvates that can form in
multiple ratios or non-stoichiometrically will show multiple hysteresis. If solvate is found
to bind only to the surface, it is easily removed and usually appears as a linear increase in
mass with increasing RH.96 Solvent that is incorporated into the crystal lattice will not
instantly be removed; this is illustrated in Figure 2.14, as well. Once the solvate has formed,
it takes a significant decrease in humidity to remove it from the lattice.97

Figure 2.14: Hysteresis shown for an API with the
capability to form a solvate. Relative humidity is
increased gradually and then reduced.94
Solution NMR is not a useful technique to determine the amount of solvent present due to
contaminations. Often the solvate is a hydrate, and water is found in many deuterated
solvents.98 A more appropriate method is to use thermal analysis such as DSC and TGA
(thermogravimetric analysis). DSC will show the removal of solvent as an endothermic
peak. Due to intermolecular interactions, solvent will evaporate above its boiling point.
Channel solvent is usually removed much easier and closer to boiling temperatures. TGA
monitors the weight loss as a substance is heated. The percentage lost (assuming the API
has not decomposed) will correspond to how much solvent has been removed, which can
then be used to calculate the ratio of sovent:API.99
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2.6 Excipient Selection and Solid State Screening
The excipient that is chosen for inclusion into a drug’s solid state should increase the
solubility and consequently the bioavailability of the drug. This is mainly done by choosing
molecules that are water soluble and have plenty of potential for intermolecular bonding. 100
It is also ideal to pick an excipient with a melting point lower than the API for reasons
previously mentioned. The principal approach used in choosing an appropriate molecule is
the supramolecular synthon method, which evaluates the potential intermolecular bonds
between separate constituents of the multi-component solid state.101 Illustrated in Figure
2.15 are both hetero- and homosynthons: one involving a bond that interacts with the same
type of bond (e.g. carboxylic-carboxylic) and the latter being dissimilar bond types
interacting with each other (e.g. carboxylic-amide). It was reported that heterosynthons are
more energetically stable; however, homosynthons are still a feasible means of
intermolecular bonding.102 The proposed intermolecular bonding should be strong enough
to displace the bonding of the single components with themselves in order to synthesize
the aforementioned solid states.
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Figure 2.15: Hydrogen bonding motifs of (a) carboxylic-carboxylic
homosynthon and (b) a carboxylic-amide heterosynthon.
A database of approved excipients is easily accessible from the FDA. 103 Table 2.5 is an
example of the results for the molecule ethylparaben (EPB). This excipient is pre-approved
for use in drugs both orally and topically with potency varying depending on the method
administered. If, for example, to form a co-crystal between an API and EPB, it should be
in a ratio that will not cause EPB to be administered more than ~0.6 mg per dose.
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Table 2.5: Inactive Ingredient Search for Approved Drug Products, EPB

Inactive

Route

Dosage Form

Ingredient
Ethylparaben

CAS

UNII

Number
Oral

Granule, For

Maximum
Potency

120478

14255EXE39

0.6 mg

120478

14255EXE39

0.66 mg

120478

14255EXE39

0.6 mg/2 g

Oral Solution
Ethylparaben

Oral

Powder, For
Oral Solution

Ethylparaben

Oral

Powder, For
Solution

Ethylparaben

Oral

Solution

120478

14255EXE39

0.6 mg/5 mL

Ethylparaben

Oral

Suspension

120478

14255EXE39

2 mg/5 mL

Ethylparaben

Topical

Emulsion,

120478

14255EXE39

NA

Cream
Where CAS is Chemical Abstracts Services, UNII is Unique Ingredient Identifier and EPB is ethylparaben.

Another source that researchers can use when choosing excipients is the Generally
Regarded as Safe (GRAS) database, which is also published by the FDA. 104 Based on
current studies, molecules are given an evaluation from 1-5, and the meanings of these
ratings are specified in Table 2.6. Ascorbic acid, also known as vitamin C, is given a
conclusion of 1 since it is well studied and known to be safe for consumption.
Conclusions 1 and 2 are acceptable excipient choices for solid state modifications. This
database, however, can lead to some misleading results (e.g. nutmeg is listed as class 3,
but it is ingested frequently in food). Also, since these inactive ingredients are not
necessarily approved for use in drug products, new clinical testing may need to be
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conducted. The preferred method for excipient choice should be the Inactive Ingredient
Search for Approved Drug Products Database.
Table 2.6: Types of Conclusions from the Selection Committee on GRAS Substances
Type of

Definition

Conclusion
1

There is no evidence in the available information on [substance] that demonstrates, or
suggests reasonable grounds to suspect, a hazard to the public when they are used at
levels that are now current or might reasonably be expected in the future.

2

There is no evidence in the available information on [substance] that demonstrates a
hazard to the public when it is used at levels that are now current and in the manner
now practiced. However, it is not possible to determine, without additional data,
whether a significant increase in consumption would constitute a dietary hazard.

3

While no evidence in the available information on [substance] demonstrates a hazard to
the public when it is used at levels that are now current and in the manner now
practiced, uncertainties exist requiring that additional studies be conducted.

4

The evidence on [substance] is insufficient to determine that the adverse effects
reported are not deleterious to the public health should it be used at former levels and in
the manner formerly practiced.

5

In view of the almost complete lack of biological studies, the Select Committee has
insufficient data upon which to evaluate the safety of [substance] as a [intended use].

Another source for finding excipients is the Everything Added to Food in the United States
(EAFUS) lists.105 As the name states, these lists include chemicals that the FDA has
approved for additives in food.106 It is theorized that if the substance is safe for ingestion,
then it can be used to some extent for oral administration.
The databases mentioned above are suitable to use when choosing an appropriate solvent
for solvate formation; however, perhaps a more appropriate method is to use the ICH’s
(International Council for Harmonisation of Technical Requirements for Pharmaceuticals
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for Human Use) guideline for residual solvents. Solvents are given a Class 1-3 where Class
1 should be avoided for use in pharmaceutical production, 2 should be limited and 3 has
low toxic potential. For solvate formation, one should only consider Class 3 solvents that
have a permitted daily exposure of 50 mg or more.107
The molecule that is added for intermolecular interaction with the API may not always be
an inactive ingredient. Recently, drug-drug compounds have become of increasing interest;
they have been employed to reduce number of prescriptions, reposition drugs, reduce
production cost and increase therapeutic effect.108 It has been shown that combining
antihypertension drugs that display poor aqueous solubility via co-crystal, co-amorphous
mixture and eutectic formation leads to increased antihypertension activity. 109 As an
outcome, number of prescriptions and production costs should decrease.
Now that an appropriate excipient has been chosen, which is arguably the most difficult
task in this approach of crystal engineering, an extensive screening process must
commence. While solid state formation procedures are well studied, they are still not
necessarily well understood, especially in terms of which combinations will form novel
solid states; therefore, proper screening is essential for successful crystal engineering. 110
An extremely efficient means of screening involves grinding API and potential excipient
together at varying molar ratios and collecting the DSC thermographs at a heating rate of
10K/min. This can only be done when there is no decomposition of the components before
their melting.111 When done without the presence of solvent (neat grinding), this technique
is considered “green” and does not complicate the system with possible solvate formation
such as with LAG.112 If the resulting phase diagram gives a “w” shape, then co-crystal
formation is possible; if a “v” shape is determined then there is likely a eutectic or coamorphous product. If the melting endotherms are found not to converge, then the resulting
product is merely a physical mixture, such as the illustration in Figure 2.16.113
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Figure 2.16: Binary phase diagram of an API and excipient
incapable of forming intermolecular interactions (physical mixture).
For a more rapid screening, one can merely run the DSC for ground mixtures of 1:1, 1:2 and
2:1 molar ratios of API:excipient.114 One scenario is the presence of a melting endotherm that
is distinct from the melting of the starting materials and is found at a consistent temperature
in all three ratios. If the PXRD pattern shows novel peaks, then co-crystal formation is
possible. Another scenario is the presence of an endothermic peak found lower than the
melting temperature of the API or excipient that will alter slightly with varying molar ratio.
Running PXRD will indicate if the product is co-amorphous or a eutectic.
While these techniques are both effective and reliable, they are not applicable for solvate
formation, and sometimes solvent effects promote the formation of different solid states (e.g.
a co-crystal that can be synthesized from solution but not from LAG). Solution methods
usually involve dissolving API (and often excipient) in solvent(s) and seeing what product is
obtained via slow evaporation and/or cooling. Another technique is to create a
suspension/slurry that is allowed to equilibrate at ambient conditions. 115 A clear drawback is
that crystallization may occur slowly, and solubility issues could lead to single phases
crystallizing out. Conceivably, screening with solvent(s) should be run in parallel to the DSC
methods mentioned, so multiple solid states can be screened simultaneously. Using solvent
mixtures helps decrease the solubility differences between API and excipient and can promote
co-crystal over solvate formation if low enough solvent concentrations are employed.116
Another screening method, known as the Kofler technique, employs hot stage microscopy and
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is useful for solid state screening. One component is melted and allowed to solidify, then a
second molten phase is introduced. This partially solubilizes the first component in the second
and a mixing zone is created that contains a concentration gradient (Figure 2.17). In this
mixing zone, a novel solid state may form under suitable conditions. Light microscope is used
to observe the number of melting points while heating.117 One melt is relevant for coamorphous and eutectic mixtures, while two melts are seen for co-crystal. Co-crystal
formation will result in a crystalline phase at the interface.118

Zone of
Mixing

API

Excipient

Figure 2.17: API (higher melting point) is melted
and recrystallized before excipient is brought
into contact which creates a zone of mixing.117

With appropriate screening and sufficient excipient/solvent selection, one can efficiently
obtain a novel solid form that will potentially display increased solubility and bioavailability.

Summary
The FDA releases dozens of NMEs per year for pharmaceutical usage, and most of these drugs
have very low aqueous solubility (i.e. the highest dose strength is soluble in more than 250
mL water over a pH range of 1 to 7.5). The solubility of Class II and IV drugs can be improved
through the crystal engineering technique of adding another molecule into the crystal lattice
of the API. This molecule should be pre-approved for use in pharmaceuticals and not interact
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with the API. Use of this type of excipient requires no clinical testing, which is very
advantageous to industry. Potential excipients can be narrowed down using a computer-based
software that statistically analyzes molecular complementarity of the API with a list of
common co-formers established from their molecular structure. Another technique, called the
molecular synthon approach, will analyze the potential intermolecular bonding of the API and
find corresponding excipients. Once a list of excipients is chosen, they should be screened
using solvent crystallization in parallel with grinding and DSC techniques.
Should the screening result in the formation of a novel solid state, it is essential that it is
appropriately identified. The first step should be to have the proper characterization of both
the API and the excipients used; this will lead to an easy comparison and solid state analysis.
Next, one should run PXRD on the new product. For the solid states mentioned in this review
(i.e. co-amorphous mixtures, co-crystals, eutectics and solvates), there are three different
outcomes from the evaluation of the PXRD patterns. If the product’s pattern shows no new
peaks and appears as a combination of the starting materials, then the result is either a physical
mixture or a eutectic. If there are peaks that are distinct from the starting materials (and their
polymorphs) or an entirely new pattern is observed, then the resulting solid state could either
be a co-crystal or solvate. The final option is to observe a “halo” in which there is simply one
very broad peak. This pattern is characteristic of an amorphous material.
A good idea at this point would be to run 1H NMR on the product and compare it to that of
the starting materials. Are the chemical shifts corresponding to the API present? How about
the shifts for the excipient or solvent? Solution NMR is a valuable tool to ensure that the API
did not decompose and determines what is present in their product. If a PXRD pattern of the
product resulted in novel peaks and 1H NMR revealed that the excipient (or solvent) was
present, then the result is most likely a co-crystal (or solvate). Likewise, if the PXRD pattern
was amorphous and both starting materials are present in the NMR spectrum, then the product
is co-amorphous. 1H NMR cannot be used to help elucidate physical mixtures from eutectics.
The next step would be to run thermal analysis to validate the formation of a new solid state.
If there is a single peak in DSC that is distinct from the melting of the starting materials, then
the product is a co-crystal. If there is a mixture of co-crystal and starting material, then three

41

peaks should be observed: one for eutectic melt, one for co-crystal melt and one for the
melting of excess API. The melting point of the co-crystal is usually seen between the melting
points of the starting materials. Solvates will often result in a thermograph that shows the
evaporation of solvent in the lattice above its boiling point, followed by the melting of the
API. TGA should be run on potential solvates to see if the weight loss corresponds to solvent
loss. Co-amorphous mixtures are not predictable in their DSC thermographs but will often not
show the melting of the starting materials, and an exothermic peak will be present. Physical
mixtures will simply show the melting of each starting material in DSC, while eutectics will
melt below the lower melting point starting material (usually excipient). DSC is also useful
to plot phase diagrams. Eutectics and co-amorphous systems will give a “v” shape, while cocrystals will result in a “w” shape. The melting points in physical mixtures will not converge,
so no such shape will be present.
These techniques are usually sufficient in determining what solid state is formed, but they can
be aided by ssNMR, FT-IR and Raman. The ultimate tool would be to determine the molecular
structure from single crystal XRD, but often it is difficult to grow crystals of appropriate
quality. After a novel solid state is formed, the rate that dissolves should be determined and
compared with that of the API through intrinsic or powder dissolution rate studies. If the novel
product is found to have an increased solubility compared to the API, then a viable alternative
to the API has been synthesized. The same can be said if the dissolution rate is increased,
since the API will have only a limited time in solution (i.e. in the body). The pharmaceutical
company can now investigate patenting and eventually distributing this form.
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Chapter 3
Crystallization of Esomeprazole Magnesium Water/Butanol
Solvate
The molecular structure of esomeprazole magnesium derivative in the solid-state is
reported for the first time along with a simplified crystallization pathway. The structure
was determined using single crystal X-ray diffraction technique to reveal the bonding
relationships between esomeprazole heteroatoms and magnesium. The esomeprazole
crystallization process was carried out in 1-butanol and water was utilized as anti-solvent.
This compound proved to be esomeprazole magnesium tetrahydrate with two 1-butanol
molecules that crystallized in P 63 space group, in a hexagonal unit cell. Complete
characterization of a sample after drying was conducted by the use of powder X-ray
diffraction

(PXRD),

1H

nuclear

magnetic

resonance

spectroscopy

(NMR),

thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), infrared
spectroscopy (IR), and dynamic vapor sorption (DVS). Investigation by 1H NMR and TGA
has shown that the solvent content in the dried sample consists of two water molecules and
0.3 butanol molecules per one esomeprazole magnesium molecule. This is different from
the single crystal X-ray diffraction results and can be attributed to the loss of some water
and 1-butanol molecules stabilized by intermolecular interactions. The title compound,
after drying, is a true solvate in terms of water; conversely, 1-butanol fills the voids of the
crystal lattice in non-stoichiometric amounts.

Introduction
Esomeprazole, the (S)-enantiomer of omeprazole, is the first single optical isomer proton
pump inhibitor.1 This eutomer forms an active inhibitor achiral sulphenamine when in the
acidic compartment of the parietal cell. The activated form of omeprazole prevents the
formation of gastric acid by blocking the enzyme H+/K+-ATPase, which is accountable for
the formulation of gastric acid and is found in the secretory membranes of the parietal cell. 2
The stability of this active pharmaceutical ingredient (API) is a function of pH and acidic
conditions must be avoided. In acidic conditions, omeprazole can degrade to form at least
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five distinct impurities. These degradants do not inhibit the production of gastric acid and
reduce the competence of the pharmaceutical.3 Omeprazole has been documented to
decompose up to 10% in air due to moisture.4 Esomeprazole has been presented in various
forms of alkaline salts as a means of increasing stability. The salt of interest is
esomeprazole magnesium, which has a half-life of 19 hours at 25 °C and 8 hours at 37 °C
while at pH 6.5
Omeprazole possesses a single stereogenic center on the sulfur atom and is by definition a
racemic mixture of the (R) and (S) enantiomers. The (S)-enantiomer of this API is found
in higher concentrations in plasma membrane compared to the (R)-enantiomer because it
is more slowly and less variably metabolized. The intrinsic clearance is three times lower
for esomeprazole, meaning longer resonance time in vivo. The active inhibitor formed is
the same for both isomers and as a result they have the same effect on the body 6. Shown
in Figure 0.1, esomeprazole displays tautomerism of the benzimidazole N-H hydrogen
atom, resulting in 5-methoxy and 6-methoxy tautomers. In solution, both tautomers are
present but the 6-methoxy derivative is favoured nearly 2:1.7 According to 1H and

13C

NMR studies, the 6-methoxy tautomer is the only form present in the solid state.8 It has
also been confirmed through crystallographic analysis that the 6-methoxy derivative is
more stable.9 This combination of chirality and tautomerism allows for a wide range of
possible crystalline structures of this API.

Figure 0.1: The 5-methoxy and 6-methoxy tautomers of omeprazole.
A potential technique to stabilize esomeprazole is to form a solvate by incorporating
solvent molecules into the crystal lattice of the API via intermolecular forces. In a “true”
solvate, Figure 0.2 (a), the solvent molecules become included in the unit cell in
stoichiometric amounts. The crystal structure will collapse when solvent is removed from
these solvates. Alternatively, solvent molecules can fill the voids and channels of the
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crystal structure in non-stoichiometric amounts. These types of solvates, shown in Figure
0.2 (b), will remain crystalline when solvent is removed.10 When forming a solvate, one
must be vigilant in ensuring that the incorporated solvent is not toxic to the consumer at a
given dosage.11 Minimal research articles have been published exploring the possibility of
esomeprazole solvates, though a crystalline form of omeprazole sodium ethanol solvate
has been reported.12,13

(a)

(b)

Figure 0.2: A simplified visualization of (a) a “true” solvate vs (b) a nonstoichiometric solvate, where the solvent can be one or more types of solvent.
Analogous to many prospective APIs, the instability of esomeprazole poses concerns for
industry in manufacturing and storage.14 Since water is present throughout many industrial
processes, one attempt at stabilization is through the investigation of possible
pseudopolymorphs, such as hydrates. Pharmaceutical hydrates occur when water becomes
incorporated into the crystal lattice of an API by means of intermolecular bonding.15 The
small size relative to most pharmaceuticals, as well as the hydrogen bonding ability of
water, make it an ideal molecule to incorporate into the crystal lattice.16 To date, there are
patented examples of esomeprazole magnesium in tetrahydrate, trihydrate, dihydrate,
monohydrate and hemihydrate forms.17,18 In a study of esomeprazole magnesium hydrates,
it was found that the stability order in water is trihydrate > dihydrate form A > tetrahydrate
> dihydrate form B. The solubility order in water was determined to be dihydrate form B
> tetrahydrate > dihydrate form A > trihydrate.19
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Materials and Methods
Esomeprazole magnesium (MW= 713.12 g/mol) was provided by Apotex Pharmachem
Inc. and kept in an inert environment when in storage. 1-butanol was purchased from
Fischer Scientific and used in crystallization. All 1H NMR spectra were obtained from
solutions in DMSO-d6 purchased from Sigma Aldrich.
A Bruker Apex II Diffractometer with Mo X-ray radiation was used to obtain the crystal
structure of the title compound. Powder X-ray Diffraction was obtained from a Rigaku
Miniflex instrument with Cu X-ray radiation. Scans were run at a speed of 1.00°/minute
for 2θ values of 2.00-40.00°. Thermogravimetric analysis and differential scanning
calorimetry were conducted on the Mettler-Toledo STARe 851e and 822e instruments,
respectively, at a heating rate of 5 °C /minute from 25-350 °C. 1H NMR spectrum was
collected on a Mercury VX 400 MHz machine. IR results were obtained over 32 scans
from 4000 cm-1 to 500 cm-1 using a Nicolet 6700 FT-IR spectrometer. DVS-1000, from
Surface Measurement Systems Ltd., was used to obtain results for dynamic vapor sorption.
The esomeprazole magnesium water/butanol solvate was obtained by dissolving 0.750 g
of amorphous esomeprazole magnesium in 7.0 mL of 1-butanol. Once in solution, it was
filtered to obtain a clear solution, then 1.0 mL of distilled water was added and stirred until
miscible. The solution was kept overnight at 5.0 °C. Crystalline powder was formed which
was filtered and washed with 1-butanol. Surface solvent was removed by heating under
vacuum at 50-55 °C for up to 16 hours. The single crystal sample was obtained by
dissolving 0.700g of amorphous esomeprazole magnesium in 40.0 mL of 1-butanol. To the
clear solution, 2.0 mL of distilled water was added. The solution was then left at 5.0 °C for
2-3 weeks until single crystals had formed.

Results and Discussion
In the present work, a novel form of esomeprazole magnesium has been characterized by
single crystal X-Ray diffraction, powder X-ray diffraction (PXRD),

1H

NMR

spectroscopy, infrared spectroscopy (IR), thermogravimetric analysis (TGA), differential
scanning calorimetry (DSC) and dynamic vapour sorption (DVS). The trihydrate form is
known to be soluble in methanol, ethanol and 1-butanol.20 The solubility in ethanol is low,
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and methanol is toxic to humans. Since 1-butanol is on the FDA approved list of
solvents/excipients, the esomeprazole magnesium water/1-butanol solvate was further
investigated. Additionally, crystallization of this solvate was particularly simple and
moderately short.
Existing literature contains the single crystal structures for omeprazole and toluene
hemisolvate piperazinium esomeprazolate.9,21,22 To better understand the bonding and
structure of esomeprazole derivatives, various efforts were made at forming single crystals.
Plate like single crystals were formed from a solution of amorphous esomeprazole
magnesium in 1-butanol in the presence of water at 5 °C after approximately three weeks.
The sample was mounted on a Mitegen polyimide micromount with a small amount of
Paratone N oil. All X-ray measurements were made on a Bruker Kappa Axis Apex2
diffractometer at a temperature of 110 K. The unit cell dimensions were determined from
a symmetry constrained fit of 9907 reflections with 6.4° < 2θ < 46.62°. The data collection
strategy was a number of ω and ϕ scans which collected data up to 51.468° (2θ). The frame
integration was performed using SAINT.23 The resulting raw data was scaled and
absorption corrected using a multi-scan averaging of symmetry equivalent data using
SADABS.24 The structure was solved by using a dual space methodology using the
SHELXT program.25 All non-hydrogen atoms were obtained from the initial solution. All
hydrogen atoms except for water molecules were introduced at idealized positions and
were allowed to ride on the parent atom. The hydrogen atoms on the water molecules were
added considering hydrogen bonding with nitrogen or oxygen atoms around them. The
structural model was fit to the data using full matrix least-squares based on F2. The
calculated structure factors included corrections for anomalous dispersion from the usual
tabulation. The structure was refined using the SHELXL-2014 program from the
SHELXTL suite of crystallographic software.26 Graphic plots were produced using the
Mercury program suite (Summary of crystal data in Table 0.1).27 CCDC 1468173 contains
the supplementary crystallographic data for this paper. These data can be obtained free of
charge

from

The

Cambridge

www.ccdc.cam.ac.uk/data_request/cif.

Crystallographic

Data

Centre

via
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Table 0.1: Summary of Crystal Data.
Formula
Formula Weight (g/mol)
Crystal Dimensions (mm)
Crystal System
Space Group
Temperature, K
a, Å
b, Å
c, Å
,°
,°
,°
V, Å3
Z
F(000)
 (g/cm)
, Å, (MoK)
, (cm-1)
R1
wR2
GOF
Maximum shift/error
Min & Max peak heights on final F Map (e-/Å)

C126H198Mg3N18O36S6
2806.30
0.185 × 0.142 × 0.092
Hexagonal
P 63
110
14.701(4)
14.701
39.123(11)
90
90
120
7323(5)
2
3000
1.273
0.71073
0.185
0.0674
0.1733
1.032
0.000
-0.497, 0.487
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Figure 0.3: Esomeprazole magnesium molecules crystalize in P 63 spaces group
alongside with water and 1-butanol molecules; the molecules of the same colour are
symmetry equivalent.
Molecules of esomeprazole magnesium crystallize in the space group P 6 3, with Z = 2,
alongside four water and two 1-butanol molecules (C126H198Mg3N18O36S6) (Figure 0.3). As
it is shown in Figure 0.4, coordination around the magnesium centers is octahedral. For
every Mg center that has six water molecules around it, there are two magnesium centers
that are coordinated with three esomeprazole ligands. All of the esomeprazole molecules
act as chelating ligands and coordinate the Mg centers with one oxygen as well as one
nitrogen atom. This agrees with previous DFT calculations, where omeprazole was shown
to favour coordination with Co(II) and Fe(III) through the sulfoxide oxygen and the
benzimidazolic nitrogen.28 All of the six water molecules that are coordinated to the
magnesium center show hydrogen bonding either with other water molecules in the lattice
or the nitrogen atoms in the esomeprazole ligands (Figure 0.5). 1-Butanol molecules fill
the voids in this lattice and are also hydrogen bonded to the water molecules in the lattice.
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Figure 0.4: Two types of coordination around the magnesium centers, hydrogen
atoms and non-bonded solvents have been omitted for clarity. Mg: green, S: yellow,
O: red, N: blue, C: grey.

Figure 0.5: Strong hydrogen bonding between the molecules in the lattice are shown
in blue dotted lines; hydrogen atoms have been omitted for more clarity. Mg: green,
S: yellow, O: red, N: blue, C: grey.
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From the single crystal structure, the powder pattern was simulated and is shown in Figure
0.6. This pattern is different than that of the crystals which have been dried under vacuum.
In the pattern of the dried sample, the peaks at 2θ = 7° and 8° are much lower in intensity.
As well, the simulated peak at 2θ = 4.5° has shifted to 5.1°; however, the peak at 2θ = 18.5°
is consistent in both simulated and experimental powder pattern. Some solvent molecules
have been removed from the lattice, and as a result, a different polymorph according to the
PXRD pattern is formed. This is further proved by other characterization techniques that
are discussed below. As seen in the single crystal analysis, water is found in the channels
of the lattice along with being bonded to the magnesium cation. The dative covalent
bonding of water to the magnesium is much stronger than the hydrogen bonding displayed
by the channel water molecules. The change in PXRD pattern shows that the crystal lattice
has changed by removing some of the water and 1-butanol molecules. The pattern obtained
of the solvate after drying is comparable to that of esomeprazole magnesium dihydrate
form A, with equivalent peaks at 2θ = 5° and 18°.29 The X-ray pattern was consistent for
the sample after drying under vacuum at 50 °C for two hours and up to 16 hours. The
powder diffraction also remained the same for samples that were exposed to air. Since
esomeprazole is known to be chemically unstable in air, the ability of the esomeprazole
magnesium water/1-butanol solvate to remain crystalline in air highlights a potential
advantage for its use in pharmaceutical solid dosage forms.
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Figure 0.6: X-ray powder diffraction of esomeprazole magnesium water/butanol
solvate calculated from single crystal structure and esomeprazole magnesium
water/butanol solvate after drying under vacuum.
In order to confirm the occurrence of 1-butanol in the crystal lattice after drying, 1H NMR
data was collected from the dry sample in DMSO-d6 solution (see Appendix A, Figure A1). The presence of water and 1-butanol is clear by analysis of the spectrum; esomeprazole:
1H

NMR δ 8.25 (m, 1H), 7.37 (d, J=8.6 Hz, 1H), 7.02 (d, J=2.6 Hz, 1H), 6.60 (dd, J=2.5

Hz, 8.4 Hz, 1H), 4.72 and 4.46 [d (AB system, J=12.7 Hz, 2H)], 3.75 (s, 3H), 3.70 (s, 3H)
2.21(s, 6H); 1-butanol: 1H NMR δ 4.30 (t, 2H), 3.38 (q, 1H), 1.39 (m, 2H) 1.30 (m, 2H)and
0.83 (t, 3H); Water: 1H NMR δ 3.3 (s, 2H).30,31 Since it was assumed that all surface water
and solvent are removed after sufficient drying, the characteristic peaks were integrated to
determine the 1-butanol content. As previously stated, esomeprazole will demonstrate
tautomerism in solution. DMSO-d6, a slow exchange solvent, was utilized in an effort to
help reduce these effects in solution.32 The multiplet occurring at 8.25 ppm is characteristic
of esomeprazole, uneffected by tautomerism, and signifies a single proton, while the triplet
at 0.84 ppm is representative of the methylene protons of 1-butanol. Integrating these peaks
confirmed that there are still 0.3 1-butanol molecules per esomeprazole magnesium in the
dried sample. Water, seen at 3.33 ppm, cannot be accurately quantified in this method due
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to inevitable impurities in the NMR solvent. These impurities arise from DMSO’s affinity
for water; it cannot be dried completely over molecular sieves. 33
The structure of esomeprazole magnesium dihydrate/1-butanol solvate contains many
different functional groups. IR spectroscopy was utilized to help confirm the presence of
esomeprazole, water and 1-butanol after a sample had been dried under vacuum (see
Appendix A, Figure A -2). Table 0.2 shows the absorption frequencies for these functional
groups. The peaks presented are characteristic of esomeprazole with a broad peak at
approximately 3000 cm-1 from the O-H stretching in water and 1-butanol. The peak
representative of the N-H in the benzimidazole, usually seen around 3400 cm -1, is not
observed. This is due to overlapping with the frequencies of the O-H stretching from
coordinated and non-coordinated solvent molecules. Compared to free esomeprazole, no
change in frequency is seen for the pyridinic nitrogen. This agrees with the molecular
structure determined with single crystal XRD, where esomeprazole is coordinating through
benizimidazolic nitrogen and sulfoxide oxygen. The frequencies observed are in close
agreement with the calculated IR spectra for omeprazole co-ordinated to different metal
centers.28
Table 0.2: IR spectroscopy absorption frequencies and corresponding functional
groups.
Functional
Group

Absorption Frequency
(cm-1)

sulfoxide
methoxy
methoxy
amine
pyridine
benzimidazole

1076
1199
1228
1409
1569
1612, 1588

aromatic

2970

alcohol/water

3100-2800

Type of Vibration
S=O stretching34
C-O stretching34
C-O stretching34
N-H bending28
C=N stretching28
C=N stretching28
C=C-H asymmetric
stretching34
O-H stretching35
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In an attempt to confirm the total solvent content in the crystal lattice, thermogravimetric
analysis (TGA) was performed. The TGA results revealed two mass losses for this solvate.
The first step can be attributed to the loss of solvent in the lattice, while the second step
can be accredited to the decomposition of the sample. The desolvation resulted in a loss of
7.6% of the total mass. These results are consistent with the 1H NMR analysis of 0.3 1butanol and two water molecules per esomeprazole magnesium. The spectrum obtained
from TGA confirms that the esomeprazole magnesium water/1-butanol solvate loses
solvent from the lattice when dried under vacuum. TGA was also conducted after heating
the sample to 120°C under vacuum, and the same results were acquired. The second mass
loss begins at 200 °C, typical for the decomposition of esomeprazole magnesium.29

Figure 0.7: TGA of the title sample showing two mass losses. The first loss of 7.6% is
desolvation, while the second loss is decomposition of the esomeprazole molecule.
Differential scanning calorimetric analysis was performed on the esomeprazole
magnesium water/1-butanol solvate as well (Figure 0.8). The pattern shown can be
described as an exothermic melting via decomposition. Amorphous esomeprazole
magnesium is known to display an exothermic peak at approximately 200 °C.36 When DSC
was run on the starting material, the exothermic peak was seen at 181°C. From Figure 0.8,
the water/1-butanol solvate decomposes at 200 °C. This increase in decomposition
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temperature implies an increase in stability. The peak shown below is broader than that of
the amorphous API; the width at half height is 13.3 °C, while the width is 5.8°C for
amorphous esomeprazole magnesium. The broadening agrees with the results from TGA
and 1H NMR that show solvent is still present in the lattice. In addition to this peak, the
DSC curve of the title compound also shows an endotherm at 175 °C. This curve matches
known results for esomeprazole magnesium dihydrate, which aids in validating the
assumption that some of the solvent is being removed after vacuum drying, leaving
esomeprazole magnesium dihydrate with some 1-butanol molecules.17

Figure 0.8: The DSC curve of esomeprazole magnesium water/1-butanol solvate. The
curve was obtained from 25-350 °C at a heating rate of 5 °C/minute. An exotherm
characteristic of esomeprazole magnesium is seen at 200 °C as well as an endotherm
at 175 °C.
The stability of this compound is further investigated by DVS; the subsequent isotherm is
shown in Figure 0.9. In sorption cycles 1 and 2, there is a 5.3% mass increase. The
adsorption/desorption of water is a reversible process in the title compound. Since the
sample reverted to the initial mass, the water adsorbed can be said to be on the surface of
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the API. The behaviour of this isotherm implies that the structure of the title compound is
highly crystalline.

DVS Isotherm Plot

5.5

Change In Mass (%) - Ref

4.5
3.5
2.5
1.5
Cycle 1 Sorption
0.5
Cycle 1 Desorption
-0.5
Cycle 2 Sorption
-1.5

Cycle 2 Desorption

-2.5
0

20

40
60
Target RH (%)

80

100

Figure 0.9: Esomeprazole magnesium water/1-butanol adsorption of water at
increasing humidity followed by desorption at decreasing humidity. The cycle is
repeated to give two isotherms.

Conclusion
This is the first single crystal structure reported that displays esomeprazole coordinated to
a metal center. Analysis of the crystal structure shows that water is bound to magnesium
cation as well filling the channels of the lattice. The covalently bonded waters are much
more strongly kept in the lattice than those maintained by hydrogen bonding. The discovery
of this esomeprazole magnesium solvate could have applicability to the development of
improved pharmaceutical solid dosage forms.
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Chapter 4
Co-amorphous form of curcumin-folic acid dihydrate with
increased dissolution rate
Curcumin is a naturally occurring pharmaceutical derived from turmeric. Despite its many
medicinal properties, such as being an antioxidant, anti-inflammatory, tumor reducer, etc.,
applications of curcumin are restricted due to its low aqueous solubility and consequently
its poor bioavailability. By converting the solid state of poorly water soluble active
pharmaceutical ingredients to co-amorphous mixtures, solvates, co-crystals and eutectics,
the solubility can be significantly improved. In this study, US Food and Drug
Administration (FDA) approved excipients were screened for their ability to form novel
solid states with curcumin to increase its aqueous solubility. Excipients were screened
based on their molecular complementarity with curcumin that was determined using
Mercury software. From this screening, it was found that a co-amorphous mixture can be
formed between curcumin and folic acid dihydrate that has potential as a prenatal or a
women’s health drug due to its use in preeclampsia and ovarian cancer treatments. This
mixture was found to have an increased dissolution rate when compared with curcumin.
After one hour, 175 mg/L of curcumin was dissolved from the co-amorphous mixture,
while only 45 mg/L was dissolved from curcumin Form I. The co-amorphous mixture is
stable as it was shown to keep its amorphous behavior after 24 hours in solution at elevated
temperatures. Eutectics were found to form between curcumin and biotin, carbmazeapine,
ethyl paraben, paracetamol, suberic acid, succinic acid and L-tyrosine. Screening with
other excipients led to no novel solid state formation; however, an improved synthesis
method for curcumin Form II in the presence of dextrose is presented.

Introduction
Curcumin, with many potential applications as an antioxidant1, anti-inflammitory2,
colourmetric sensor3, tumor reducer4, holds a high level of interest in food and
pharmaceutical industries. Though it is safe for ingestion up to 8000 mg/day5, curcumin is
limited in function due to its extremely low water solubility (<0.1 mg/mL), which leads to
inadequate bioavailability.6 Curcumin is unstable and known to decompose in neutral and
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basic conditions. Degradation products include trans-6-(4'-hydroxy-3'-methoxyphenyl)2,4-dioxo-5-hexenal as the major product, while vanillin, ferulic acid and feruloyl methane
are the minor products.7 Vanillin has been shown to have its own pharmaceutical
applications, but since its concentration is extremely low as a degradation product, it cannot
be claimed as the reason for curcumin’s bioactivity.8 All of these products have low
toxicity, but degradation occurs rapidly. In order to increase its prevalence in commercial
use, the stability and solubility issues of this naturally occurring active pharmaceutical
ingredient (API) need to be addressed.
Changing the solid form of the API as a means of increasing its solubility is a very popular
technique in the pharmaceutical industry. Common solid forms include salts, solvates,
eutectic mixtures, co-crystals and co-amorphous mixtures. Salts occur from the formation
of ionic bonds between an API and one or more excipients. A solvate occurs when solvent
molecules are incorporated into the lattice during crystallization through intermolecular
bonding. A eutectic mixture is composed of fine crystals of each component that are mixed
very closely, and when an API forms a eutectic with a water soluble compound, the
dissolution rate of the drug increases.9,10 Co-crystals, which have been steadily gaining
interest in the pharmaceutical industry11, are more comparable to solvates. They are
composed of two or more components, termed API and co-former(s), that are
intermolecularly bonded (mainly hydrogen bonding) to form a crystal lattice. All
components of a co-crystal are found in stoichiometric amounts and should be overall
neutral and solid at ambient conditions.
Co-amorphous solids occur when two components become amorphous due to interaction
with one another. Intermolecular bonding between API and excipient impedes the
arrangement of individual molecules into separate lattices and results in an amorphous
material.12 Amorphous pharmaceutical compounds have been shown to have increased
solubility in comparison to their crystalline counterparts. For instance, indomethacin,
glucose, glibenclamide, griseofluvin, iopanoic acid and polythiazide were all
experimentally shown to have solubility ratios (amorphous:crystalline) ranging from 1.4 to
24.13–18 Since the amorphous form is the most energetic, this solid state should greatly
increase solubility and bioavailability.13 However, compounds that are amorphous have
been shown to have low stability and will tend to crystallize if exposed to moisture.19 Co-
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amorphous mixtures are shown to be not only high in solubility, but also possess high
stability and are easily formed via grinding or milling. Co-amorphous systems have shown
to not only increase the dissolution rates relative to crystalline materials, but also compared
to their individual amorphous components.20 Co-amorphous mixtures of naproxen,
indomethacin, simvastatin, carbamezapine, ritonavir and lurasidone hydrochloric acid with
various excipients show increases in dissolution rate up to 200-fold when compared to
starting materials.21–28 Various amino acids have been displayed to form co-amorphous
mixtures with low solubility APIs and were stable up to 4-6 months at 40 °C/0% relative
humidity, which is much longer than most amorphous drugs.
Since co-crystals have shown the ability to enhance solubility and bioavailability of Class
II and IV drugs29–38, attempts were made to produce co-crystals of curcumin using several
co-formers. Before choosing potential co-formers for co-crystallization, a thorough
literature review was carried out to understand current state of the art. Curcumin has been
reported to form co-crystals with several co-formers listed in Table 0.1. However,
formation of co-crystals is not always successful and sometimes results in eutectic
mixtures; some known curcumin eutectics have been listed in Table 0.2. Curcumin, which
has an intrinsic dissolution rate (IDR) of 0.0061 (mg/cm2)/min39, showed an increase in
IDR for all of these solid forms (reported in Tables 4.1 and 4.2). The most successful cocrystal is with pyrogallol, showing well over a tenfold increase in IDR and nearly five times
as soluble in 40% ethanol.40 There is also a drug-drug co-amorphous mixture of curcumin
and artemisinin with an IDR that is 2.6 times faster than curcumin in 60% EtOH.41 The
next most successful solid state, with IDR of 0.0647 IDR (mg/cm2)/min, is the eutectic
mixture of curcumin with nicotinamide.39 Some co-formers that simply resulted in a
physical mixture include: L-maleic acid39, catechol40 and orcinol.40
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Table 0.1: Known Curcumin Co-crystals and Their Intrinsic Dissolution Rates.
Co-former

IDR
(mg/cm2)/min

Co-former

IDR
(mg/cm2)/min

2-aminobenzimidazole41

0.023

nicotinamide23

0.040

4-4’-bipyridine-N,N’-dioxide42

NR

phloroglucinol43

0.0166

caffeinea, 44

NR

piperazine44

NR

ibuprofen sodium44

NR

piperidine44

NR

isonicotinamide44

NR

L-prolinea,44

NR

L-lysine41

0.029

pyrogallol40

0.09364

methylparaben45

NR

resorcinol40

0.03761

naproxen sodium44

NR

aAPI

is the curcumin derivative bisdesmethoxycurcumin
IDR = Intrinsic dissolution rate
NR = not reported
Table 0.2: Known Curcumin Eutectics and Their Intrinsic Dissolution Rates.
Co-former

IDR
(mg/cm2)/min

ferulic acid39

0.0412

hydroquinone39

0.0344

p-hydroxybenzoic acid39

0.0270

nicotinamide39

0.0647

l-tartaric acid39

0.0132

In addition to increasing the bioavailability, co-crystals, as well as co-amorphous and
eutectic mixtures have also been employed to increase therapeutic effect, reduce the
number of prescriptions and reposition drugs by means of drug-drug combinations.46 Since
curcumin is known to be anti-inflammatory, it could be combined with another antiinflammatory drug to increase potency or combined with a drug that is usually prescribed
alongside an anti-inflammatory drug to reduce the number of prescriptions. In this work,
we have made attempts to prepare new solid forms of curcumin, including drug-drug
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mixtures. While the main aim was to produce co-crystals, eutectics have been formed along
with a co-amorphous form of curcumin and folic acid dihydrate (CUR-FAD) with
enhanced dissolution rate.

Experimental
Materials and Instruments
Succinic acid, L-tyrosine and ethanol were purchased from Fisher Scientific (Mumbai,
India), Alfa Aesar (Hyderabad, India) and Chemcon Specialty Chemicals Pvt Ltd
(Vadodara, India), respectively. All other chemicals purchased were from Sigma Aldrich
Chemicals Pvt Ltd (Bangalore, India).
DSC analyses of solid samples were carried out on a NETZSCH STA 449F3 Jupiter
(NETZSCH-Gerätebau GmbH; Selb, Germany) from 25-350℃ at a heating rate of
10K/min, unless otherwise stated. Phase diagrams were obtained from plotting both the
onset of the first endotherm and the peak temperature of the second endotherm. Powder
X-ray Diffraction (PXRD) studies were carried out using a Rigaku Miniflex instrument
with Cu X-ray radiation. Scans were run at a speed of 1.00°/minute for 2θ values of 2.0040.00°. Infrared (IR) Spectroscopy results were obtained over 32 scans from 4000 cm -1 to
500 cm-1 using a Vector 22 FT–IR spectrometer (Bruker; Milton, Canada).

Preparation and characterization of curcumin and folic acid dihydrate
(CUR-FAD) co-amorphous mixtures
Liquid assisted grinding (LAG) with 5 drops of methanol was executed on equimolar
amounts of curcumin and folic acid dihydrate using mortar and pestle for varying amounts
of time.

Equilibrium solubility and powder dissolution studies
UV-Vis

(ultraviolet

visible)

spectrophotometer

(Agilent

Cary

60

UV-Vis

Spectrophotometer, Agilent Technologies, Santa Clara, USA) was used for estimation of
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equilibrium solubility and powder dissolution rates. Three calibration curves (see
Appendix B) were constructed using known concentrations of curcumin, folic acid
dihydrate and CUR-FAD so the amount of curcumin and folic acid dihydrate released could
be determined. The extinction coefficients were determined to be 45.4, 28.0 and 39.1
L/mmol cm, respectively. Thermodynamic solubility was estimated by adding an excess of
CUR-FAD (~20 mg) into 2 mL of 40% EtOH solution. The suspended solutions were
allowed to stir at 37oC for over 24 hours. This was done in triplicate and concentration was
determined using calibration curves.
To estimate dissolution kinetics, nine samples were prepared by adding excess
(determined from thermodynamic solubility) CUR-FAD, which had been sieved through a
150µm mesh, into 4 mL of 40% EtOH solution. The solutions were stirred at 3.2 Hz and
37 oC for a specified amount of time. Each sample was filtered using Arodisc 25 mm
syringe filters with 0.45µmSupor membrane (Pall Corporation; Port Washington, USA),
immediately diluted and concentration was estimated using UV-Vis spectroscopy. Powder
dissolution studies were conducted in triplicate and the average values have been reported.

Results and Discussion
Solid State Formation
To increase the amount of curcumin absorbed by the body and improve its applications in
the pharmaceutical industry, several co-formers were screened to explore their ability to
form different solid states with curcumin. The excipients investigated should be safe for
human ingestion to have feasible pharmaceutical and food applications. Critical to
successful screening is the choice of appropriate co-formers that will form strong
intermolecular bonds. Using the molecular complementarity tool in Mercury, 47 which takes
into account factors such as molecular shape and polarity, a list of potential co-formers was
constructed based on the molecular structure of Form I curcumin, the stable form.48 It
should be noted that, like the successful co-formers that form solid states with curcumin,
Mercury predicted success with heterosynthons (e.g. curcumin with carboxylic and amine
functional groups), utilizing the enol as the strongest probable intermolecular bonding site.
The list shown in Table 0.3, was then condensed to only include compounds suitable for
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pharmaceutical applications. Analyzing the list, comparing it to the known co-crystals of
curcumin and using the compounds present in the laboratory, led to the screening of
succinic acid, suberic acid, ibuprofen, paracetamol, oxalic acid, l-tyrosine, Nacetyltryptophan, carbamezapine, ethylparaben, folic acid, biotin and dextrose.
Table 0.3: FDA Approved Potential Co-formers for Curcumin Co-crystals.
Co-former

Co-former

Adipic acid

L-methionine

L-arginine

L-phenylalanine

t-butylhydroxyanisole

Propylparaben

Capsaicin

Sorbic acid

Ethylparaben

Suberic acid
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Folic acid

Succinic acid

L-glutamic acid

L-tryptophan

Lactose

L-tyrosine

A recognized co-crystal screening technique uses DSC (differential scanning calorimetry)
as a rapid method for assessing potential co-formers. In this technique, DSC is run for three
different ratios (1:1, 1:2 and 2:1) of the components.49 This should result in two endotherms
representing the eutectic melt and melting of the co-crystal; each endotherm should be
distinct from the melting of the API and co-former. Using this screening process, one can
usually surmise if an API and co-former have capability of forming a co-crystal or eutectic.
In case of ambiguous results, a phase diagram should be constructed. After running DSC
for samples ground at varying molar ratios of curcumin and co-former, it was determined
whether co-crystal formation was viable or if a eutectic would form. These results are
confirmed with PXRD which will show new peaks for co-crystals, a combination of the
peaks of the starting materials for eutectic and physical mixtures, or an amorphous pattern
for co-amorphous mixtures. From analysis of PXRD and DSC, it was determined that
physical mixtures were formed with dextrose, N-acetyltryptophan, and ibuprofen. This can
be seen by the example with dextrose given in Figure 0.1 (a), where there is clearly no
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converging in the phase diagram. Eutectics formed with biotin, carbamazepine, ethyl
paraben, paracetamol, suberic acid, succinic acid and L-tyrosine. A phase diagram for the
eutectic with suberic acid is given in Figure 0.1 (b). When combined with the PXRD shown
in Figure 0.2, it is made clear that the product is a eutectic and not a co-crystal or coamorphous mixture. None of the screened co-formers were found to form crystals with
curcumin; however, a co-amorphous mixture with folic acid dihydrate (CUR-FAD) was
formed.

(a)

(b)

Figure 0.1: Phase diagram for (a) the physical mixture of curcumin and dextrose and
(b) the eutectic mixture of curcumin and suberic acid after grinding at varying molar
ratios. Temperatures plotted in blue represent the onset of the first melting peak seen
in DSC, while orange represents the temperature of the second peak.
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Figure 0.2: PXRD patterns for (a) raw suberic acid, (b) raw curcumin, (c) curcumin
form I, (d) form II, (e) form III, (f) 1:1 curcumin:suberic acid (CUR-SUB), (g) 1:2
CUR-SUB, (h) 2:1 CUR-SUB, (i) 1:3 CUR-SUB, (j) 3:1 CUR-SUB, (k) 1:4 CUR-SUB,
(l) 4:1 CUR-SUB acid and (m) 4:1 CUR-SUB acid heated to 133℃.

Following the screening protocol, curcumin and folic acid dihydrate were initially ground,
and PXRD patterns were recorded for 10, 20, 30, 60 and 90 minute intervals of liquid
assisted grinding. As shown in Figure 0.3, the final product remained amorphous after
grinding for 90 minutes. The PXRD patterns clearly show the loss of crystallinity, which
is different when compared with the PXRD patterns of raw curcumin and folic acid
dihydrate. In addition to PXRD, DSC heating experiments were also conducted throughout
the grinding process. Error! Reference source not found. shows DSC thermographs for
ground samples and those for curcumin and folic acid dihydrate. It is observed that the
melting endotherm of curcumin at around 180oC is not present in the ground product and
instead there is an exothermic peak (seen in Error! Reference source not found. (a) and
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(b)). The magnitude of the peak corresponding to curcumin melting decreases gradually
with heating, which indicates transition to an amorphous phase by grinding. These results
clearly indicate that liquid assisted grinding (LAG) of curcumin with folic acid dihydrate
results in a co-amorphous solid.

Exothermic

Figure 0.3: PXRD patterns for CUR-FAD from LAG after (a) 90 min, (b) 60 min, (c)
30 min, (d) 20 min, (e) 10 min, (g) raw folic acid dihydrate and (h) raw curcumin.

Figure 4.4: DSC thermograph for CUR-FAD from LAG after (a) 90 min, (b) 60 min,
(c) 30 min, (d) 20 min and (e) 10 min (f) raw folic acid dihydrate and (g) raw curcumin.
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To ensure that there is no decomposition of the starting materials and that a co-amorphous
mixture is forming, both 1H NMR and FT-IR spectra were obtained for the ground samples.
It is clear from Figure 0.5 that the solution NMR spectrum of CUR-FAD in DMSO-d6
shows the characteristic peaks of curcumin as well as folic acid dihydrate. Also, there is no
excess peak that would correspond to the decomposition of curcumin nor folic acid
dihydrate.

Figure 0.5: solution 1H NMR spectra for (a) CUR-FAD, (b) raw folic acid dihydrate
and (c) raw curcumin in DMSO-d6.
Normalized FT-IR spectra are shown in Figure 0.6, and analysis suggests interactions
between curcumin and folic acid dihydrate but no decomposition. It should be noted that
the peaks in the 3500-3200 cm-1for the N-H stretching in folic acid dihydrate lose their
intensity; this is most likely due to the involvement of weak intermolecular bonding with
the API. The peak for the phenolic O-H stretching in curcumin50 at 3509 cm-1 is not seen
in the spectrum of the co-amorphous product, and the carbonyl stretching51 at 1691 cm-1 of
folic acid dihydrate is shifted to 1697 cm -1for CUR-FAD. There is also a shift in the
carbonyl stretching of curcumin from 1627 cm -1 to 1623 cm-1, implying that it is involved
in the interaction, too. No indication of degradation during grinding in addition to
implications for increased interaction between curcumin and FAD further confirms that a
co-amorphous solid phase has been formed.
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Figure 0.6: FT-IR spectra for (a) CUR-FAD, (b) raw folic acid dihydrate and (c) raw
curcumin.

Solubility and Dissolution Rate Tests
Since the objective in forming a new solid state with curcumin was to increase the amount
absorbed in the body, powder dissolution rate studies were conducted. Excess amount of
CUR-FAD was placed in nine separate vials which were then each filled with 2 mL of 40%
EtOH solution at 37oC. Vials were stirred at 3 Hz for up to 4 hours, filtered and diluted,
then analyzed using UV-Vis spectrophotometer. Figure 0.7 shows dissolution profiles for
raw curcumin and the co-amorphous solid. When compared with curcumin, there is an
increase in dissolution rate for the co-amorphous product. The dissolution rate for the coamorphous product was found to be similar to the pyrogallol co-crystal (about 182 mg of
curcumin/L after 4 hours), which has the largest increase in IDR compared to other
curcumin co-crystals. Thermodynamic equilibrium solubility studies were also conducted
over 24 hours at 37oC by adding excess CUR-FAD to 2 mL of 40% EtOH solution. It was
found that 458 ± 25 mg/L and 328 ± 31 mg/L of curcumin and folic acid dihydrate were
dissolved, respectively. Using the area under the curve, the amount of curcumin dissolved
in four hours from the co-amorphous mixture is 41.2 ± 3.8 g h/L, which is much greater
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than that of curcumin form I (12.2 g h/L).25 The PXRD pattern of the remaining powder in
solution after 24 hours is shown in Figure 0.8. The overall pattern is still amorphous in
nature, but characteristic peaks can be seen at 2θ values of 17.3 and 8.9 for curcumin and
13.0 and 10.9 for folic acid dihydrate. Thus, it can be stated that the co-amorphous mixture
is still relatively stable since it remains highly amorphous in nature after 24 hours in
solution at an elevated temperature.

Figure 0.7: Powder dissolution rate studies for CUR-FAD compared with
curcumin.25
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Figure 0.8: PXRD pattern of powder from thermodynamic equilibrium solubility.

Folic acid is a form of the water soluble vitamin B-9, and it is highly encouraged to take
during pregnancy for both maternal and fetal health. 52 Curcumin is also known to reduce
placental inflammation, a common symptom of preeclampsia that occurs in up to 8% of
pregnancies.53,54 When combined, this new drug-drug combination has the potential to be
repositioned as a prenatal drug. Both curcumin and folic acid have been shown to be
effective in the treatment and pre-treatment of ovarian cancer; once again, this could lead
to a reposition of this co-amorphous mixture as a women’s health drug and could
potentially lead to a lower number of drugs prescribed.55,56

Formation of Curcumin Form II
When performing solution crystallization to synthesize curcumin co-crystals, Form II
curcumin crystals were found to grow in the presence of dextrose. Solution crystallization
was performed for this pair due to ambiguity in the PXRD patterns (i.e. appeared to show
novel peaks). While this was not the initial aim of these experiments, it is still beneficial
since this curcumin polymorph has a faster dissolution rate. It is the metastable polymorph,
so Form II is generally not stable and will not form easily relative to Form I. Since it is
crystallized in the presence of dextrose, this makes the process safer for pharmaceutical
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and food applications. Also, this procedure does not involve dimethyl sulfoxide, a difficult
to remove solvent, nor cooling like some known processes.40 A simple method is proposed
from which Form II crystals can be grown via slow evaporation, or by rapid evaporation
(i.e. heating the solution close to boiling point of solution), from a solution of 90%
methanol with equimolar dextrose present. The crystals grown were of X-ray quality and
resulted in the confirmation of Form II curcumin that crystallizes in the orthorhombic space
group of P ca21 (shown in Figure 0.9).58 Further research should be conducted to test the
validity and feasibility of this method on a larger scale.

Figure 0.9: Asymmetric unit of Form II curcumin with space group of P ca21 formed
via slow evaporation from 90% methanol in the presence of dextrose. Hydrogen
atoms are omitted for clarity. C: grey; O: red.

Conclusion
Curcumin is a natural drug product that is found to have many health benefits; however,
its use in industry is limited by its very low aqueous solubility. To increase the
bioavailability of curcumin, screening for a novel solid state was conducted. The excipients
screened were chosen using a combination of the supramolecular synthon approach,
computational molecular complementarity and knowledge of known curcumin co-crystals.
It was found that physical mixtures would form with dextrose, N-acetyltryptophan, and
ibuprofen, while eutectics would form with biotin, carbmazeapine, ethyl paraben,
paracetamol, suberic acid, succinic acid and L-tyrosine. Of particular interest of this work
is the result of screening with folic acid dihydrate. Folic acid dihydrate was chosen due to
its approved molecular complementarity with curcumin. A novel solid state of curcumin is
presented in this paper as a co-amorphous mixture with folic acid dihydrate (CUR-FAD).
Using liquid assisted grinding, the mixture became co-amorphous. This mixture, which can
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be repositioned in the pharmaceutical industry as a prenatal, has shown to dissolve faster
than curcumin in aqueous solutions. At 60 minutes, 175 mg/L of curcumin is dissolved
from CUR-FAD; this is much more efficient than curcumin, which is found to dissolve
about 40 mg/L at 60 minutes. The co-amorphous mixture is found to keep its amorphous
behaviour after 24 hours in solution at 37oC. Further work should be conducted to see the
stability of this mixture. Co-amorphous mixtures have been shown to be more stable than
a single amorphous compound but retain the increased solubility and dissolution rates;
therefore, more excipients should be screened for this type of solid state. An improved
method is given for the formation of metastable curcumin Form II crystals which is
industry friendly since it is done in the presence of dextrose and no methanol is included
into the molecular structure.
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Chapter 5
Efforts to Increase the Solubility of Rufinamide
Rufinamide is an active pharmaceutical ingredient (API) that is used to treat a form of
childhood epilepsy called Lennox-Gastaut syndrome that is characterized by having
multiple seizure types. This API has a broad-spectrum antiepileptic with low adverse
effects. Rufinamide is considered a Class IV API by the Biopharmaceutics Classification
System, which means that it has low solubility and low permeability. Since patients with
Lennox-Gastaut syndrome are usually children and are often taking multiple medications,
it would be advantageous to increase the solubility of this drug to reduce the required
dosages. To date, there are no salts, co-crystals, solvates, etc. of this drug; its structural
polymorphs are the only solid state forms discovered. We attempted to increase the
dissolution rate of rufinamide by choosing potential excipients and conducting extensive
screening to form co-crystals or other solid state forms. No novel solid states of rufinamide
with excipients were produced. The excipients that were chosen all had potential to form
intermolecular bonds and passed a computer-based screening test. However, the molecular
structure of a metastable polymorph termed modification B of rufinamide was obtained.
Also reported is an accelerated procedure to produce modification B in the presence of
citric acid.

Introduction
Lennox-Gastaut syndrome is a serious form of childhood epilepsy characterized by
multiple seizure types and often cognitive impairment. This syndrome frequently continues
into adulthood, and the seizures are generally not responsive to typical antiepileptic drug
care.1 Rufinamide (shown in Figure 0.1) is an anticonvulsant that acts by reducing the firing
of sodium dependent action potentials in treating patients with Lennox-Gastaut syndrome.2
This API is a broad-spectrum antiepileptic drug with low drug interaction and good adverse
event profile.3 While it is proven to be effective, this drug has very poor aqueous solubility
and relatively low permeability, so it is considered to be BCS (Biopharmaceutics
Classification System) Class IV.4
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To date, there are no known co-crystals, solvates, eutectics or co-amorphous mixtures
involving rufinamide; however, there are multiple polymorphs.5,6 A polymorph is a solid
crystalline phase of a given compound resulting from the possibility of at least two different
arrangements of molecules of that compound in the solid state.7 Some of these polymorphs
are given below in Table 0.1. Modification A is shown to have better thermodynamic
stability; Modification C will transform to A or B at room temperature. The molecular
structures of these polymorphs are not given in the CSD (Cambridge Structural Database).
Table 0.1: Some polymorphs of rufinamide
Polymorph

Space Group

Crystal System

Modification A

Pna21

orthorhombic

Modification B

P-1

triclinic

Modification C

P21/C

monoclinic

Looking at the chemical structure in Figure 1, there are multiple sites for potential
intermolecular bonding between rufinamide and excipient molecules. Supramolecular
synthons are structural units within supermolecules which can be formed and/or assembled
by known or conceivable synthetic operations involving intermolecular interactions.8 Since
amide groups are known to form both heterosynthons (e.g. with carboxylic acids) and
homosynthons, molecules with either type of functional group should be screened for
potential novel solid state forms with rufinamide.9

Figure 0.1: Molecular structure of rufinamide.
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Materials and Methods
Rufinamide modification A was donated by Apotex Pharmachem Inc. (Branford, Canada).
Solvents and excipients were obtained from Sigma Aldrich (Oakville, Canada). Screening
of excipients for solid states was done via liquid assisted (ethanol) and neat grinding at
various molar ratios for 20 minutes with mortar and pestle. Solution crystallization in
various solvent systems was also attempted at varying molar ratios via slow evaporation at
ambient conditions or cooling crystallization at a rate of 10 °C /hour. Theses screenings
did not result in novel solid state formation. Bulk modification B was obtained by
dissolving citric acid (100 mg) and rufinamide modification A (100 mg) in DMSO (6 mL)
at 40°C for 2 hours. The mixture was turbid, so filtration was required and an additional 1
mL of DMSO was added. Next, the solution was left at atmospheric conditions until
needle-like crystals formed that were filtered and dried under vacuum at 60°C for three
hours. Single crystals were grown via slow evaporation from methanol at ambient
conditions, and Bruker Apex II Diffractometer with Mo X-ray radiation was used to obtain
the crystal structure. 1H NMR spectrum was collected on a Mercury VX 400 MHz machine.
Powder X-ray Diffraction was obtained from a Rigaku Miniflex instrument with Cu X-ray
radiation. Scans were run at a speed of 1.00°/minute for 2θ values over 2° to 40°.
Thermogravimetric analysis and differential scanning calorimetry were conducted on the
Mettler-Toledo STARe 851e and 822e instruments, respectively, at a heating rate of 10
°C/minute from 25-350 °C.

Results and Discussion
Since Class IV drugs are undesirable, increasing the solubility of rufinamide was attempted
through solid form screening. Co-crystal screening via grinding and solution methods was
conducted in an attempt to form novel solid states of rufinamide with a host of excipient
molecules. To help choose an appropriate co-former, multi-component screening based on
molecular complementarity was conducted via Mercury software. 10 This software uses the
shape, polarity and hydrogen bonding potential of the API to determine which excipients
(from a list of the most commonly used co-crystal formers) may form a co-crystal based
on the statistics of other co-crystal forming pairs. At the time of screening, none of the
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molecular structures of rufinamide’s polymorphs were available in the Cambridge
Structural Database (CSD). While it is not essential to have the molecular structure of the
API to use this screening technique (e.g. a 3D drawing of the molecule would suffice),
much more accurate results can be obtained if the structure of the API is available. Methyl
1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylate, an intermediate in the synthesis of
rufinamide, is accessible in the CSD and contains an ester as opposed to the amide group
seen in Figure 0.1. The crystal was shown to form weak intermolecular C-H⋯O and CH⋯N hydrogen bonds that link the molecules into chains along the b-axis.11 This molecular
structure was modified by simply changing the functional group to an amide so that it
exemplified rufinamide. Once modified, this compound resulted in an extensive list of
potential co-formers for co-crystal formation. This list led to many possible excipients to
screen, so it was narrowed to include only those approved by the US Food and Drug
Administration (FDA) that had strong capability to form intermolecular bonds. Excipients
screened included citric acid, urea, thiourea, nicotinamide, sorbitol, L-(+)-histidine, Lthreonine, ascorbic acid, 4-aminobenzoic acid, propylene glycol, folic acid dihydrate, Lalanine, L-glutamic acid, mandelic acid, succinic acid, lactose monohydrate, chitosan and
L-tyrosine. Many different screening techniques, such as solvent crystallization and the
grinding/DSC methods were employed as an attempt to form a novel solid state. Though
extensive screening with many excipient molecules was conducted, no novel co-crystals,
co-amorphous, solvates or eutectic mixtures were discovered.

Rufinamide Modification B
In order to investigate the underlying reason, successful attempts were made to grow single
crystals of rufinamide modification B and its molecular structure was obtained through
single crystal XRD (X-ray diffraction). By dissolving rufinamide modification A in
methanol and allowing slow evaporation, modification B crystallized out as colorless,
needle-like crystals. While this unit cell is known, its molecular structure is not published
and, as mentioned, cannot be found in the CSD. The sample was mounted on a Mitegen
polyimide micromount with a small amount of Paratone N oil. All X-ray measurements
were made on a Bruker Kappa Axis Apex2 diffractometer at a temperature of 110 K. The
unit cell dimensions were determined from a symmetry constrained fit of 9962 reflections
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with 5.02° < 2𝜃 < 68.16°. The data collection strategy involved ω and ϕ scans up to 68.602°
(2θ). The frame integration was performed using SAINT. 12 The resulting raw data was
scaled and absorption corrected using a multi-scan averaging of symmetry equivalent data
using SADABS.13 The structure was solved by using a dual space methodology using the
SHELXT program.14 All non-hydrogen atoms were obtained from the initial solution. All
hydrogen atoms were introduced at idealized positions and were allowed to ride on the
parent atom. The structural model was fit to the data using full matrix least-squares based
on F2. The calculated structure factors included corrections for anomalous dispersion from
the usual tabulation. The structure was refined using the SHELXL-2014 program from the
SHELXTL suite of crystallographic software.15 Graphic plots were produced using the
Mercury program suite (Summary of crystal data in Table 0.2).16
Table 0.2: Summary of Crystal Data of Rufinamide Modification B.
Formula
Formula Weight (g/mol)
Crystal Dimensions (mm)
Crystal System
Space Group
Temperature, K
a, Å
b, Å
c, Å
𝛼,°
𝛽,°
𝛾,°
V, Å3
Z
F(000)
𝜌 (g/cm)
𝜆, Å, (MoK𝛼)
𝜇, (cm-1)
R1
wR2
GOF
Maximum shift/error
Min & Max peak heights on final ΔF Map (e-/Å)

C10H8F2N4O
238.20
0.377 × 0.137 × 0.086
Triclinic
P -1
110
5.2943(10)
11.936(5)
17.121(6)
71.540(14)
87.719(9)
77.255(8)
1000.5(6)
4
488
1.581
0.71073
0.133
0.0632
0.1131
1.033
0.001
-0.287, 0.519
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Modification B of rufinamide was found to crystallize in the space group P-1 with Z = 4.
The packing in the unit cell is shown in Figure 0.2. Intermolecular N-H⋯O hydrogen
bonding occurs between the amide groups of distinct molecules (Figure 3). There is also
N-H⋯N bonding between amide groups and nitrogen of the triazole. The bond lengths
range from 2.890 to 3.057 Å and are representative of strong hydrogen bonding between
molecules. The shortest and strongest intermolecular bonds are the N-H⋯O bonds (i.e.
bonds a, b and c in Figure 0.3), which is known to be a convincing homosynthon.
Intriguingly, the homosynthon is formed between three distinct rufinamide molecules as
opposed to two molecules, which is more common. This is evidently illustrated in Figure
0.4. The presence of an amide strengthens the intermolecular bonding, which is noticeable
when compared to the weak hydrogen bonding of the rufinamide derivative mentioned
earlier. It is worth mentioning that halogen bonding was observed in the structure of
rufinamide between fluorine groups and the aromatic benzene rings of individual
molecules. Weak intermolecular bonding is also seen between hydrogen molecules of the
CH2 group and the triazole nitrogen.
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Figure 0.2: Molecules of rufinamide modification B in one unit cell. F: green, O: red,
N: blue, C: grey and H: white.

(a) 2.890 Å

(d) 3.057 Å
(b) 3.038 Å

(c) 2.937 Å
Figure 0.3: Strong hydrogen bonding between the molecules in the lattice are shown
in black dotted lines (labelled a-d); hydrogen atoms have been omitted for more
clarity. F: green, O: red, N: blue, C: grey.
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Figure 0.4: Intermolecular homosynthons between (a) two and (b) three amide groups
from distinct molecules.

Further Screening
Once the molecular structure of rufinamide modification B was obtained, it was possible
to run the multi-component screening through Mercury using the molecular structure of
the modification B, instead of a compound with a structure similar to rufinamide, as
discussed earlier. A much narrower list of potential co-formers was obtained, which could
lead to more accurate screening. For instance, succinic acid was a potential co-crystal
former with the modified rufinamide intermediate; however, it did not pass the statistical
screening with rufinamide modification B due to issues with shape and size
complementarity. The FDA approved list from the second screening computer generated
group of suggested co-formers is given in
Table 0.3. Some of the potential co-formers that were suggested for the modified
rufinamide derivative showed negative results for co-crystal formation with modification
B. This coincides with the statement that co-crystal formation is very dependent on the
shape of the molecule, not solely hydrogen bond formation capabilities. 10
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Table 0.3: FDA approved co-formers from CSD screening with rufinamide
modification B
L-arginine

L-tyrosine

L-methionine

lactose

L-phenylalanine

citric acid

L-tryptophan

capsaicin

Another extensive screening was conducted, but this time with modification B as the
starting solid form of the API and the co-formers listed above; however, still no new solid
states were discovered. This was peculiar due to the many potential sites for hydrogen
bonding in rufinamide. Also, triazole derivatives have been shown to readily form cocrystals with compounds containing carboxylic acid groups.17
When analyzing the chemical structure of rufinamide, it seems like a good candidate for
incorporating an excipient into the crystal lattice. There are multiple sites for hydrogen
bonding (e.g. amide, triazole and halogen functional groups) and its low aqueous solubility
makes it an interesting target for co-crystal, co-amorphous, eutectic or solvate formation.
Additionally, the Z’ value (i.e. the molecules in the asymmetric unit) for rufinamide
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modification B is 2, and it has been shown that molecules with a Z’>1 have a stronger
tendency to form co-crystals.18 Furthermore, when screened for potential co-crystal coformers, many molecules were suggested with eight of them being FDA approved.. It has
also been previously shown that triazole groups are capable of forming hydrogen bonds
with dicarboxylic acids leading to the formation of co-crystals, but rufinamide was unable
to form any novel solid state with the molecules listed in Table 3.6 It was observed that
rufinamide tended to form needle-like crystals and would often form a jelly-like solution
during the crystallization process (i.e. a hydrogel). In order for a novel solid state to form,
the intermolecular bonding force between API and excipient needs to be stronger than the
API-API and excipient-excipient intermolecular bonding force. Perhaps the intermolecular
forces between molecules of rufinamide are too strong to overcome by the attempted coformer molecules. As stated, there are no solid states of rufinamide in literature that involve
excipient addition into the crystal lattice. Amide-amide bonds are very strong, and it is
shown in the crystal structure of rufinamide modification B that this homosynthon is a
stabilizing force. The high stability of the rufinamide crystal structure would also explain
why grinding did not help in the formation of any new forms: the mechanical forces were
not strong enough to break the bonds.
Another suggestion as to why no novel solid states were produced with excipient molecules
could be due to solubility issues. Rufinamide has very poor solubility in most solvents and
had to be heated to dissolve fully. Often, solvents such as dimethylformaide (DMF),
dimethylsulfoxide (DMSO) and dimethylacetamide (DMAC) were used, in which the
excipients were very highly soluble. These solubility issues could lead to the fast
crystallization of rufinamide before any co-former had the chance to interact with it.

Results from Screening with Citric Acid
While no novel solid state form was obtained through screening with citric acid similar to
other employed excipients, some interesting results were observed in the case of citric acid.
Crystals were obtained by dissolving citric acid and rufinamide modification A in DMSO;
the solution was left at atmospheric conditions until solids were formed. The crystals
obtained were filtered and dried under vacuum for solvent removal. When compared with
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the starting material (i.e. modification A), seemingly novel powder XRD (PXRD) pattern
was recorded; which is illustrated in Figure 0.5 (a). The differential scanning calorimetry
(DSC) thermograph ( Figure 0.5 (b)) appeared very similar to that of rufinamide
modification A, which is not characteristic of co-crystal formation. Solution 1H NMR
(nuclear magnetic resonance) was run to identify the main components of the solid and can
be seen in Figure 0.6. The NMR spectrum revealed that rufinamide was present (i.e. the
product’s spectrum matches that of the starting material), so the experimental conditions
did not lead to decomposition of the API. Interestingly, when compared to the spectrum of
pure citric acid, this starting material is undoubtedly absent in NMR of the product;
indicating that citric acid did not crystallize with rufinamide. These findings led to further
analysis of the PXRD pattern, which revealed that the product was the metastable
modification B. This was proven by matching the diffraction pattern with the pattern that
was simulated from the obtained single crystal results.

Figure 0.5: (a) PXRD patterns and (b) DSC thermographs for rufinamide
modification A (black) and rufinamide modification B obtained from solution
(purple).
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(a)
(b)
(c)

13

 (ppm)

2

Figure 0.6: 1H NMR spectra for (a) citric acid, (b) rufinamide modification A and (c)
rufinamide modification B in DMSO-d6.
The proposed process to obtain modification B is much quicker than slow evaporation and
resulted in a more homogeneous product with increased crystallinity. The procedure was
replicated by using different acids (summarized in Table 0.4), but the product either did
not crystallize or decomposed. Citric acid has a pKa1 of 3.08, while oxalic acid has a pKa1
of 1.23. Oxalic acid is much stronger acid and leads to the decomposition of rufinamide.
Formic acid and ascorbic acid have pKa1 values of 3.75 and 4.10, respectively. They are
not strong acids and comparable to citric acid. While rufinamide did not decompose using
these acids, it resulted in the crystallization of modification A. Next, the solvent type was
varied (i.e. DMF, DMAC), but the results could not be duplicated. Clearly, there must be
some solvent effects that are present when DMSO is used.
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Table 0.4: Attempted acids for synthesis of rufinamide modification B. 19
Acid

Structure

pKa1

Citric Acid

3.08

Formic Acid

3.75

Ascorbic Acid

4.10

Oxalic Acid

1.23

Conclusion
Lennox-Gastaut syndrome is a devastating type of childhood epilepsy that can be treated
with the drug rufinamide. This drug has been proven to be effective, but it has a low
aqueous solubility that demands higher doses. Screening was conducted using solution and
grinding methods to find other solid forms (such as co-crystals, co-amorphous, eutectic
mixtures, solvate) to increase rufinamide’s solubility and bioavailability. Although
screening did not result in the formation of a novel solid state, a novel synthesis of a
metastable form of rufinamide, modification B, was discovered. The proposed method
depended on solvent and excipient present. The molecular structure of rufinamide B, a
poorly soluble antiepileptic drug, was determined and used in computer based co-crystal
screening. The lack of novel solid states from the suggested co-formers implies that this
method is not entirely reliable if co-crystal formation is challenging and molecular synthon
approach should also be employed. Rufinamide is a small molecule with many potential
sites for hydrogen bonding, and it has rotation about a CH 2. Therefore, it should not be
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disregarded completely for formation of a novel solid state. Also, due to the nature of
Lennox-Gastaut syndrome, multiple prescriptions are used; perhaps drug-drug solid states
should also be investigated.
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Chapter 6
Conclusion and Recommendations
There is a clear need in the pharmaceutical industry to increase the solubility of new active
pharmaceutical ingredients (APIs), since many of them are considered BCS
(Biopharmaceutics Classification System) Class II and IV drugs. Increased solubility and
dissolution rate of these APIs will lead to better bioavailability, reduced dosages, less waste
and potentially fewer prescriptions; this all suggests savings for the pharmaceutical
industry. In this thesis, three low solubility APIs (i.e. esomeprazole magnesium, curcumin
and rufinamide) were all investigated for their ability to form novel solid states. This was
done by screening with excipients that are approved for use in drugs and would expectantly
interact with the API through intermolecular bonding. Formation of solid states was
confirmed by a combination of powder and single crystal X-ray diffraction, differential
scanning calorimetry, thermogravimetric analysis, solution nuclear magnetic resonance
spectroscopy and dynamic vapour sorption. Further screening on these drugs can be
conducted to find more novel states.

Conclusions
Esomeprazole magnesium is a low solubility drug used to treat chronic acid reflux. To
improve this API, screening was conducted using solution crystallization and grinding
techniques. What was obtained was a solvate with both water and 1-butanol present. High
quality single crystals of this novel solid state were crystallized and the molecular
structures were determined using X-ray diffraction. This is the first single crystal structure
reported that displays esomeprazole coordinated to a metal center. The esomeprazole acts
as a bidentate ligand, with three molecules coordinated to a single magnesium center.
Magnesium cations are also shown to co-ordinate to water molecules, and water is
furthermore shown to be filling the channels of the crystal lattice along with nonstoichiometric amounts of butanol molecules. The covalently bonded waters are much
more strongly kept in the lattice than those maintained by hydrogen bonding. When heated
under vacuum the channel solvents were removed to reveal the dihydrate of esomeprazole
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magnesium. This solvate will have similar solubility to the dihydrate since it has the same
crystal structure. The discovery of this esomeprazole magnesium solvate could have
applicability to the development of improved pharmaceutical solid dosage forms.
Found in a variety of Asian cuisine, turmeric is a common spice that contains curcumin, a
natural drug product that is found to have many health benefits. The use of curcumin in the
pharmaceutical and food industries is often limited by its lack of aqueous solubility. In this
thesis, screening for a novel solid state of curcumin with a variety of excipients was
conducted. To narrow the search, a computer-based method was employed to predict which
co-formers would form co-crystals with form I (most common and stable) curcumin. Folic
acid dihydrate is one these predicted co-formers and was displayed to form a novel solid
state with curcumin. After grinding with ethanol, a co-amorphous mixture was obtained
and confirmed by PXRD (Powder X-ray Diffraction) and DSC (Differential Scanning
Calorimetry). Repositioning of this mixture as a prenatal drug is possible since both folic
acid and curcumin are used to treat a variety of pregnancy symptoms. This would save
money and reduce the number of prescriptions needed. The co-amorphous mixture is also
advantageous because it has improved dissolution rate over curcumin in aqueous solutions.
After one hour, 175 mg/L of curcumin is dissolved in 40% ethanol from the co-amorphous
mixture. This is a vast improvement over the 40 mg/L of form I curcumin after one hour.
This mixture is also shown to be relatively stable and will keep its amorphous behaviour
after 24 hours in solution at body temperature. Co-amorphous states in the pharmaceutical
industry are relatively new and not well studied. The results confirm the validity of this
solid state form as an improvement to APIs with low bioavailability. Additionally, given
in this work is an alternative method of forming metastable form II curcumin. Crystals can
be synthesized by slow evaporation from methanol in the presence of dextrose. Powder can
be obtained from anti-solvent crystallization with water. This method is faster than current
methods of producing form II curcumin and give a high purity yield.
Rufinamide is a low solubility API that is used to treat a form of childhood epilepsy call
Lennox-Gastaut syndrome that is characterized by multiple seizure types. While this API
is proven to be effective, its solubility issues lead to increased dosages to generally young
patients. To increase this undesirable characteristic, and essentially its bioavailability,
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screening for the formation of a novel solid state was conducted. Many excipients were
screened based on the molecular structures of a modified form of rufinamide and the
metastable modification B. After extensive screening, no co-crystals, solvates, eutectics or
co-amorphous mixtures were discovered. Perhaps the strong intermolecular bonding found
in rufinamide is why it was not possible to include another molecule into its crystal lattice.
Presented is a novel synthesis route for the crystallization of modification B as well as its
molecular structure. This crystallization was found to be very dependent on the solvent
(dimethyl sulfoxide) and excipient (citric acid) employed.

Recommendations
The screening of esomeprazole magnesium was successful in finding a novel solvate form;
however, it was not practical or necessary to do dissolution rate or solubility studies
because of the channel solvates. Since the solvent molecules that were not coordinated to
magnesium were only weakly involved in intermolecular bonding, they would be easily
removed and not problematic to quantify. This would lead to difficulties in solubility
determination because molecular weight would vary for each sample. Also, since the
molecular structure so closely matched esomeprazole magnesium dihydrate, it can be
assumed to have a similarly improved solubility. Future work can be done to screen this
API more thoroughly for other solid states. Perhaps it would be easier to form co-crystals
or co-amorphous mixtures with esomeprazole as opposed to the magnesium salt. The
molecular structure of the water/1-butanol solvate was very complex and could not be used
to help determine a list of potential co-formers from Mercury. If single crystals could be
produced that display the binding of the esomeprazole molecules to magnesium without
solvent, then perhaps the software could be employed. This would help to narrow the
search for potential API-excipient combinations as well as help improve understanding of
the conceivable intermolecular interactions. The starting material used in the screening was
the amorphous form of the pharmaceutical salt. Screening could possibly be conducting by
starting with a crystalline form and comparing the result to screening with the amorphous
form.
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There were many differences in the predicted co-formers from Mercury software and the
co-crystal formers that have been shown to form curcumin co-crystals in literature. If a
greater understanding of these differences was made then perhaps it would be easier to
know which excipients would be successful. More screening can be conducted with
molecules that more closely represent those that have been shown to form novel solid
states. Since curcumin is naturally occurring, maybe it can be viewed as an excipient for
potential solid states with other drugs. The curcumin-folic acid dihydrate co-amorphous
mixture (CUR-FAD) can be further studied. By running Raman and solid state nuclear
magnetic resonance, perhaps a proposed bonding mechanism between the two molecules
can be given. Stability studies that were not possible due to time constraints should be
conducted for CUR-FAD for an extended period of time and under specific temperature
and humidity conditions.
There is definitely a need to further investigate the possibility of solid state formation with
rufinamide. With its high potential for intermolecular hydrogen bonding and having Z’
value greater than 1, it should theoretically be readily available for synthesis of co-crystals,
co-amorphous mixtures, eutectics or solvates. A wide range of excipients were attempted
based on supramolecular synthons and computational suggestions. Possibly, a lesser
emphasis should be placed upon the Mercury generated excipients, and a larger range of
pharmaceutically approved excipients should be screened. Perhaps a literature survey of
the unsuccessful co-crystallization of APIs should be conducted to further understand why
no novel states were formed. Since there are known polymorphs of this API, a different
modification could be isolated for attempts at solid state formation. It is also recommended
that a wider range of solvents be attempted for crystallization experiments.
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Appendices
Appendix A

Supporting Information for Chapter 3

% Transmittance

Figure A - 1: 1H NMR of the esomeprazole magnesium solvate.

Wavenumber (cm-1)
Figure A - 1: FTIR of the esomeprazole magnesium solvate.
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Appendix B

Calibration Curves for CUR-FAD Dissolution
Studies

When doing dissolution studies, UV-Vis is a viable means for determining the
concentration of a solution. This technique requires the formation of a calibration curve
from known concentrations that utilizes Beer’s Law (i.e. A = cl) to determine an
extinction coefficient. This extinction coefficient is then used for the concentration
calculation of unknown sample concentrations.

Figure B - 1: Calibration curve and line of best fit for raw curcumin in 40% EtOH.
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Figure B - 2: Calibration curve and line of best fit for raw folic acid dihydrate in 40%
EtOH.

Figure B - 3: Calibration curve and line of best fit for co-amorphous mixture of
curcumin and folic acid dihydrate in 40% EtOH.
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